




(72) EDMONDS, BRIAN TAYLOR, US

(71) ELI LILLY AND COMPANY, US

(51) Int.Cl.⁷ C12N 15/12, C12N 15/66, C07K 14/47, C12N 1/21,
C07K 16/18, A61K 38/17, C07H 21/04, C12P 21/00, C12N 15/00

(30) 1998/09/01 (60/098,766) US

(54) **PROTEINE 3 DE FIXATION LATENTE AU FACTEUR β DE
CROISSANCE DE TRANSFORMATION HUMAIN**

(54) **HUMAN LATENT TRANSFORMING GROWTH FACTOR- β
BINDING PROTEIN 3**

(57) The invention provides isolated nucleic acid compounds encoding polypeptides and fragments thereof, said polypeptides being related to the human TGF β latent binding protein (hLTBP) family. This invention also provides vectors and transformed heterologous host cells for expressing said polypeptides, a method of using said nucleic acids and polypeptides for inhibiting TGF β dependent activities in vitro or in vivo, as well as pharmaceutical compositions comprising said nucleic acids or polypeptides. Also provided are assays used to identify compounds which bind to said polypeptides.

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 14/47, C07H 21/04, C12N 1/21, 15/00, C12P 21/00	A1	(11) International Publication Number: WO 00/12551 (43) International Publication Date: 9 March 2000 (09.03.00)
(21) International Application Number: PCT/US99/19436 (22) International Filing Date: 30 August 1999 (30.08.99) (30) Priority Data: 60/098,766 1 September 1998 (01.09.98) US (71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): EDMONDS, Brian, Taylor [US/US]; 12990 Brighton Lane, Carmel, IN 46032 (US). (74) Agents: WEBSTER, Thomas, D. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: HUMAN LATENT TRANSFORMING GROWTH FACTOR- β BINDING PROTEIN 3		
(57) Abstract The invention provides isolated nucleic acid compounds encoding polypeptides and fragments thereof, said polypeptides being related to the human TGFβ latent binding protein (hLTBP) family. This invention also provides vectors and transformed heterologous host cells for expressing said polypeptides, a method of using said nucleic acids and polypeptides for inhibiting TGFβ dependent activities in vitro or in vivo, as well as pharmaceutical compositions comprising said nucleic acids or polypeptides. Also provided are assays used to identify compounds which bind to said polypeptides.		

HUMAN LATENT TRANSFORMING GROWTH FACTOR- β BINDING PROTEIN 3**BACKGROUND OF THE INVENTION****5 FIELD OF THE INVENTION**

This invention relates to recombinant DNA technology. In particular the invention pertains to genes and proteins that are involved in the regulation of TGF- β activity, methods for making and using same, and pharmaceutical compositions thereof.

RELATED ART

The transforming growth factor- β (TGF- β) superfamily of cytokines comprises a large number of secreted growth and differentiation factors that play important roles in embryonic development, cellular proliferation, and tissue homeostasis. The superfamily includes, for instance, the TGF- β s, the growth and differentiation factors (GDFs), the activins, and the bone morphogenetic proteins (BMPs) among others (for review see Kingsley, *Genes and Development* 8:133-146, 1994). Making up the TGF- β sub-family are five related proteins, TGF- β 1, TGF- β 2, TGF- β 3, TGF- β 4, and TGF- β 5 having 70-80% sequence identity among themselves. Each of these proteins can affect diverse cellular functions in virtually all cell types. TGF- β 1, for instance, has been shown to inhibit the proliferation of endothelial cells (Mueller, G.J. et al., *Proc. Nat. Acad. Sci.*, 84:5600-5604 (1987)), and to stimulate the proliferation of fibroblasts under certain conditions (Barnard, J.A. et al., *Biochem. Biophys. Res. Commun.*, 163:56-63, (1997)).

The TGF- β s are initially synthesized as large precursor molecules consisting mostly of disulfide-linked homodimers. During biosynthesis the mature TGF- β dimer is proteolytically cleaved and secreted as a small latent

complex consisting of a biologically inactive, noncovalently-bound complex of dimers of the amino terminal precursor remainder, designated latency associated peptide (LAP), and mature TGF- β (Miyazono et al., *J. Biol. Chem.* 263:6407-6415 (1988)). These small latent complexes are often associated with a large molecular weight binding protein called a latent TGF- β binding protein (LTBP).

The LTBP gene family consists of three members, LTBP-1, LTBP-2, and LTBP-3, having cysteine rich multidomain structures and multiple (8-20) epidermal growth factor (EGF)-like repeats in a contiguous segment. EGF motifs are commonly found in extracellular matrix proteins where they are thought to mediate high-affinity calcium binding and to provide structural stability to regions that connect other functional domains. The eight-cysteine motifs, however, are unique to the fibrillin and LTBP gene families.

There is convincing evidence that the secreted LTBP proteins bind latent growth factors, namely TGF- β s, intracellularly and facilitate their folding and secretion to proper extracellular matrix storage sites. It has also been suggested that LTBPs protect the small latent complexes from proteolytic activity which governs the activation of latent complexes (Wushan, Y. et al., *J. Bio. Chem.* 270:10147-10160, (1995)).

There is also much data to suggest that dysregulated production and activation of TGF- β is a contributing factor in fibrotic disease (Broekelmann et al., *Proc. Nat. Acad. Sci. USA*, 88:6642-6646, (1991) and Khalil et al., *J. Exp. Med.*, 170:727-737, (1989)) and tumorigenesis, as well as conditions such as human diabetic nephropathy (Hoffman et al., *Miner. Electrolyte Metab.*, 24:190-196, (1998)), bone resorption, bone formation, and cartilage formation.

BRIEF SUMMARY OF THE INVENTION

The present invention provides novel human TGF- β latent binding protein-related nucleic acid molecules, their encoded polypeptides, pharmaceutical compositions comprising same, and therapeutic uses thereof. Nucleic acids and polypeptides of the invention are referred to herein as hLTBP-3. SEQ ID NOS: 1 and 3 originate from human sources and are useful, among other things, as probes to isolate paralogous genes from humans as well as orthologous genes from other organisms.

The present invention provides, in one aspect, isolated nucleic acid molecules comprising a polynucleotide encoding specific hLTBP-3 polypeptides, hLTBP-3 polypeptide fragments, as well as variants comprising at least one domain thereof. Such polypeptides are provided as non-limiting examples by the corresponding domains, fragments and/or variants as hLTBP-3 polypeptides corresponding to at least five amino acid fragments of SEQ ID NOS: 2, 4, or 6. The hLTBP-3 polypeptides provide multiple utilities, for example, as expected pharmaceutical compounds for inhibiting the fibrotic process, treating tumors, inhibiting bone resorption, and stimulating bone and/or cartilage formation.

Furthermore, the current invention provides in one aspect a method for treating or preventing a disease in which TGF β is responsible for inducing cellular effects that lead to at least one disease state; the method comprising administering to a patient in need of such treatment, a compound that modulates the activity of TGF β .

The current invention also provides methods for treating or preventing at least one aspect of at least one vascular disease; the method comprising administering to a patient in need of such treatment, a polypeptide of the present invention that modulates at least one TGF β regulated activity. Preferred TGF β regulatable activities include, but are not limited to, plasminogen activator inhibitor-1 (PAI-1) expression and/or

activity, PAI-1 secretion, thrombomodulin expression and/or activity, TGF β secretion, and cell proliferation.

As part of the current invention, there is provided methods for identifying compounds, such as polypeptides or
5 organic molecules, that modulate the activity of TGF β (e.g., proteins or polypeptides encoded by SEQ ID NO:1 and 3, respectively), which in turn modulate the expression or activity of anticoagulant and fibrinolytic functions, namely PAI-I and TM, in the vasculature endothelium.

10 In another embodiment the present invention relates to a substantially pure polypeptide comprising the amino acid sequence which is SEQ ID NO: 2, 4, or SEQ ID NO: 6.

The present invention also provides a method for modulating TGF β regulatable activities comprising
15 administering to a patient in need of such treatment, a protein product encoded by a nucleic acid molecule having at least 70, 75, 80, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to a member selected from the group consisting of at least 30 nucleotides of at least one of
20 SEQ ID NO:1, SEQ ID NO:3, and a nucleic acid molecule that is complementary to SEQ ID NO:1 or SEQ ID NO:3. Preferred protein products for use in the current invention include SEQ ID NOS:2,4, and 6. A nucleic acid molecule having at least 70% identity to the specified sequences are preferred for use
25 in the present invention; identity of at least 95% is especially preferred. Preferred TGF β regulatable activities include, but are not limited to, PAI-1 expression and/or activity, PAI-1 secretion, thrombomodulin expression and/or activity, TGF β secretion, and cell proliferation.

30 The present invention also provides a method for modulating TGF β regulatable activities comprising administering to a cell or cells, a protein product encoded by a nucleic acid molecule having at least 70, 75, 80, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or

100% identity to a member selected from the group consisting of at least 30 nucleotides of at least one of SEQ ID NO:1, SEQ ID NO:3, or a nucleic acid molecule that is complementary to SEQ ID NO:1 or SEQ ID NO:3. Preferred protein products for use in the current invention include those as shown in SEQ ID NOS:2, 4, 6. A nucleic acid molecule having at least 70% identity to the specified sequences are preferred for use in the present invention; identity of at least 95% is especially preferred. Preferred TGF β regulatable activities include, but are not limited to, PAI-1 expression and/or activity, PAI-1 secretion, thrombomodulin expression and/or activity, TGF β secretion, and cell proliferation.

In another embodiment the present invention relates to an isolated nucleic acid compound encoding an hLTBP-3 polypeptide. Preferably, the present invention relates to an isolated nucleic acid compound that encodes a polypeptide of the invention said nucleic acid being as shown in SEQ ID NOS: 1 or 3.

The current invention also provides a method for modulating TGF β regulatable activities comprising administering to at least one cell, an organism, or a patient in need of such treatment, an antisense nucleic acid molecule having a nucleotide sequence complementary to a contiguous sequence of mRNA transcribed from a gene selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:3, wherein said antisense nucleic acid molecule hybridizes to said contiguous sequence such that translation of said mRNA is inhibited. It is preferred if the contiguous sequence includes at least fifteen nucleotides. Preferred nucleic acid molecules for use in the current invention include complementary sequences to the polynucleotides as shown in SEQ ID NO:1 or SEQ ID NO:3, as well as fragments thereof. Preferred TGF β regulatable activities include, but are not limited to, PAI-1 expression

and/or activity, PAI-1 secretion, thrombomodulin expression and/or activity, TGF β secretion, and cell proliferation.

The invention also provides methods for the identification of compounds that modulate a TGF β regulatable activity comprising administering to at least one cell or an organism a compound that modulates expression of, or the activity of the protein product of, a nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, and fragments thereof. Preferred TGF β regulatable activities include, but are not limited to, PAI-1 expression and/or activity, PAI-1 secretion, thrombomodulin expression and/or activity, TGF β secretion, and cell proliferation.

In another embodiment the present invention relates to an isolated nucleic acid molecule useful as a hybridization probe comprising SEQ ID NO: 1, SEQ ID NO: 3, or fragments thereof consisting of at least 14 contiguous base pairs.

In another embodiment the present invention relates to an isolated nucleic acid compound that encodes a polypeptide having the ability to induce or inhibit cellular proliferation wherein said nucleic acid hybridizes to SEQ ID NOS: 1 or 3 under high stringency conditions.

In another embodiment the present invention relates to a vector comprising an isolated hLTBP-3 nucleic acid compound as shown in SEQ ID NOS: 1 or 3, as well as fragments thereof.

In another embodiment the present invention relates to a vector wherein said isolated nucleic acid compound is operably-linked to a promoter sequence.

In another embodiment the present invention relates to a host cell containing a vector of the present invention.

In another embodiment the present invention relates to a method for constructing a recombinant host cell having the potential to express an hLTBP-3 polypeptide, said method comprising introducing into said host cell by any suitable means a vector of the present invention.

In another embodiment the present invention relates to a method for expressing an hLTBP-3 polypeptide in a recombinant host cell, said method comprising culturing said recombinant host cell under conditions suitable for gene
5 expression.

In another embodiment the present invention relates to a method for identifying compounds that bind a polypeptide having the translated amino acid sequence selected from the group consisting SEQ ID NOS: 2, 4, and 6 wherein said method
10 comprises the steps of:

a) admixing a substantially purified preparation of a polypeptide identified herein with a test compound; and

b) monitoring by any suitable means a binding interaction between said polypeptide and said compound.
15

In still another embodiment the present invention relates to an antibody that selectively binds a polypeptide having the translated amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, and 6.

In another embodiment the present invention relates to
20 a pharmaceutical formulation comprising as an active ingredient an hLTBP-3 polypeptide, associated with one or more pharmaceutically acceptable carriers, excipients, or diluents thereof.

In another embodiment the present invention relates to
25 a method for modulating tissue growth by administration of a therapeutically effective amount of hLTBP-3.

In still another embodiment the present invention relates to a method for inhibiting tumor growth by administration of a therapeutically effective amount of
30 hLTBP-3.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

35 The term "antibody" as used herein describes antibodies, fragments of antibodies (such as, but not limited, to Fab, Fab', Fab₂', and Fv fragments), and

chimeric, humanized, veneered, resurfaced, or CDR-grafted antibodies capable of binding antigens of a similar nature as the parent antibody molecule from which they are derived.

The terms "complementary" or "complementarity" as used herein refer to the capacity of purine and pyrimidine nucleotides to associate through hydrogen bonding to form double stranded nucleic acid molecules. The following base pairs are related by complementarity: guanine and cytosine; adenine and thymine; and adenine and uracil. As used herein, "complementary" means that the aforementioned relationship applies to substantially all base pairs comprising two single-stranded nucleic acid molecules over the entire length of said molecules. "Partially complementary" refers to the aforementioned relationship in which one of two single-stranded nucleic acid molecules is shorter in length than the other such that a portion of one of the molecules remains single-stranded.

The term "conservative substitution" or "conservative amino acid substitution" refers to a replacement of one or more amino acid residue(s) in a parent polypeptide as stipulated by Table 1.

The term "fragment thereof" refers to a fragment, piece, or sub-region of a nucleic acid or polypeptide molecule whose sequence is disclosed herein, such that the fragment comprises 5 or more amino acids, or 10 or more nucleotides that are contiguous in the parent polypeptide or nucleic acid molecule. "Fragment thereof" may or may not retain biological activity. A fragment of a polypeptide disclosed herein could be used as an antigen to raise a specific antibody against the parent polypeptide molecule. With reference to a nucleic acid molecule, "fragment thereof" refers to 10 or more contiguous nucleotides, derived from a parent nucleic acid. The term also encompasses the complementary sequence. For example if the fragment entails the sequence 5'-AGCTAG-3', then "fragment thereof" would also include the complementary sequence, 3'-TCGATC-5'.

The term "functional fragment" or "functionally equivalent fragment", as used herein, refers to a region, or fragment of a full length polypeptide, or sequence of amino acids that, for example, comprises an active site, or any other motif, relating to biological function. Functional fragments are capable of providing a substantially similar biological activity as a polypeptide disclosed herein, *in vivo* or *in vitro*, viz. the capacity to modulate cell proliferation. Functional fragments may be produced by cloning technology, or as the natural products of alternative splicing mechanisms.

The term "functionally related" is used herein to describe polypeptides that are related to the hLTBP-3 polypeptides of the present invention, said functionally related polypeptides constituting modifications of said hLTBP-3 polypeptides, in which conservative amino acid changes are present as natural polymorphic variants of the polypeptides disclosed herein. Conservative amino acid substitutions and modifications may also be engineered using recombinant DNA techniques. Functionally related polypeptides retain the biological activity of hLTBP-3, such as the ability to inhibit cell proliferation, and/or tumor growth *in vivo* or *in vitro*.

The term "host cell" refers to any eucaryotic or procaryotic cell that is suitable for propagating and/or expressing a cloned gene contained on a vector that is introduced into said host cell by, for example, transformation or transfection, or the like.

The term "homolog" or "homologous" describes the relationship between different nucleic acid molecules, or amino acid sequences, in which said sequences or molecules are related by partial identity or chemical/physical similarity at one or more blocks or regions within said molecules or sequences.

The term "hybridization" as used herein refers to a process in which a single-stranded nucleic acid molecule joins with a complementary strand through nucleotide base

pairing. "Selective hybridization" refers to hybridization under conditions of high stringency. The degree of hybridization depends upon, for example, the degree of homology, the stringency of hybridization, and the length of
5 hybridizing strands.

The term "isolated nucleic acid compound" refers to any RNA or DNA sequence, however constructed or synthesized, which is locationally distinct from its natural location.

10 The term "mature protein" or "mature polypeptide" as used herein refers to the form(s) of the protein produced by expression in a mammalian cell. It is generally hypothesized that once export of a growing protein chain across the rough endoplasmic reticulum has been initiated,
15 proteins secreted by mammalian cells have a signal peptide (SP) sequence which is cleaved from the complete polypeptide to produce a "mature" form of the protein. Oftentimes, cleavage of a secreted protein is not uniform and may result in more than one species of mature protein. The cleavage
20 site of a secreted protein is determined by the primary amino acid sequence of the complete protein and generally can not be predicted with complete accuracy. However, cleavage sites for a secreted protein may be determined experimentally by amino-terminal sequencing of the one or
25 more species of mature proteins found within a purified preparation of the protein. Furthermore, one skilled in the art of genetic engineering can construct DNA sequences encoding a putative mature protein species fused to a heterologous SP (e.g., SEQ ID NO: 5) in order to optimize
30 secretion and/or tissue distribution of the expressed protein product.

The symbol "N" in a nucleic acid sequence refers to adenine ("A"), guanine ("G"), cytosine ("C"), thymine ("T"), or uracil ("U"); "Z" designates an unknown amino acid
35 residue; "Xaa" designates any of the known amino acids.

The term "nucleic acid probe" or "probe" as used herein is a labeled nucleic acid compound which hybridizes

with another nucleic acid compound. "Nucleic acid probe" means a single stranded nucleic acid sequence that will combine with a complementary or partially complementary single stranded target nucleic acid sequence to form a
5 double-stranded molecule. A nucleic acid probe may be an oligonucleotide or a nucleotide polymer. A probe will usually contain a detectable moiety which may be attached to the end(s) of the probe or be internal to the sequence of the probe.

10 The term "orthologue" or "orthologous" refers to two or more genes or polypeptides from different organisms that exhibit sequence homology.

 The term "parologue" or "paralogous" refers to two or more genes or polypeptides within a single organism that
15 exhibit sequence homology.

 The term "plasmid" refers to an extrachromosomal genetic element. The plasmids disclosed herein are commercially available, publicly available on an unrestricted basis, or can be constructed from readily
20 available plasmids in accordance with published procedures.

 A "primer" is a nucleic acid fragment which functions as an initiating substrate for enzymatic or synthetic elongation of, for example, a nucleic acid molecule.

25 The term "promoter" refers to a nucleic acid sequence that directs transcription, for example, of DNA to RNA. An inducible promoter is one that is regulatable by environmental signals, such as carbon source, heat, or metal ions, for example. A constitutive promoter generally
30 operates at a constant level and is not regulatable.

 The terms "protein" and "polypeptide" are used interchangeably herein and are intended to mean a biopolymer comprising a plurality of amino acid residues covalently bound in peptide linkage.

35 The term "recombinant DNA cloning vector" as used herein refers to any autonomously replicating agent, including, but not limited to, plasmids and phages,

comprising a DNA molecule to which one or more additional DNA segments can or have been incorporated.

The term "recombinant DNA expression vector" or "expression vector" as used herein refers to any recombinant DNA cloning vector, for example a plasmid or phage, in which a promoter and other regulatory elements are present thereby enabling transcription of an inserted DNA, which may encode a protein.

The term "stringency" refers to hybridization conditions. High stringency conditions disfavor non-homologous base pairing. Low stringency conditions have the opposite effect. Stringency may be altered, for example, by temperature and salt concentration.

The term "low stringency" refers to conditions that comprise, for example, a temperature of about 37° C or less, a formamide concentration of less than about 50%, and a moderate to low salt (SSC) concentration; or, alternatively, a temperature of about 50° C or less, and a moderate to high salt (SSPE) concentration, for example 1M NaCl.

The term "high stringency" refers to conditions that comprise, for example, a temperature of about 42° C or less, a formamide concentration of less than about 20%, and a low salt (SSC) concentration; or, alternatively, a temperature of about 65° C, or less, and a low salt (SSPE) concentration. For example, high stringency conditions comprise hybridization in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C (Ausubel, F.M. et al. Current Protocols in Molecular Biology, Vol. I, 1989; Green Inc. New York, at 2.10.3).

The term "SSC" comprises a hybridization and wash solution. A stock 20X SSC solution contains 3M sodium chloride, 0.3M sodium citrate, pH 7.0.

The term "SSPE" comprises a hybridization and wash solution. A 1X SSPE solution contains 180 mM NaCl, 9mM Na_2HPO_4 , 0.9 mM NaH_2PO_4 and 1 mM EDTA, pH 7.4.

5 The term "substantially pure," used in reference to a polypeptide, means substantial separation from other cellular and non-cellular molecules, including other protein molecules. A substantially pure preparation would be about at least 85% pure; preferably about at least 95% pure. A "substantially pure" protein can be prepared by a variety of
10 techniques, well known to the skilled artisan, including, for example, the IMAC protein purification method.

The term "vector" as used herein refers to a nucleic acid compound used for introducing exogenous or endogenous DNA into host cells. A vector comprises a
15 nucleotide sequence which may encode one or more protein molecules. Plasmids, cosmids, viruses, and bacteriophages, in the natural state or which have undergone recombinant engineering, are examples of commonly used vectors.

The various restriction enzymes disclosed and
20 described herein are commercially available and the manner of use of said enzymes including reaction conditions, cofactors, and other requirements for activity are well known to one of ordinary skill in the art. Reaction conditions for particular enzymes are carried out according
25 to the manufacturer's recommendation.

The hLTBP-3 gene of the present invention encodes a protein that is the human homolog of the mouse latent transforming growth factor- β binding protein-3 gene. (See e.g. Wushan, Y. et al., *J. Bio. Chem.* 270:10147-10160,
30 (1995)). These proteins are often co-expressed with TGF- β s and appear to modulate the activation process of TGF- β s. Thus, the hLTBP genes and their protein products are useful for modulating the activity of TGF β . For instance, the hLTBP-3 nucleic acids and the polypeptides they encode can
35 be used to inhibit cell proliferation where such would be beneficial, for example, in treating tumors or cancers. The

hLTBP-3 gene of this invention is expressed in numerous tissues including brain, kidney, cartilage, ovary, pancreas, stomach, and spleen.

An embodiment of a hLTBP-3 DNA sequence is disclosed herein by SEQ ID NOS:1 and 3. Those skilled in the art will recognize that owing to the degeneracy of the genetic code, numerous "silent" substitutions of nucleotide base pairs could be introduced into the sequences identified herein without altering the identity of the encoded amino acid(s) or protein or protein product. All such substitutions are intended to be within the scope of the invention.

The invention further provides isolated hLTBP-3 polypeptides, as well as fragments or specified variants thereof, comprising the amino acid sequence encoded by the deposited cDNAs, or the amino acid sequences in SEQ ID NOS:2, 4, or 6.

The isolated proteins of the present invention comprise a polypeptide having at least 5 - 10 amino acids encoded by any one of the polynucleotides of the present invention as discussed more fully, supra, or polypeptides which are conservatively modified variants thereof.

Exemplary polypeptide sequences are provided in SEQ ID NOS:2, 4, and 6. The proteins of the present invention or variants thereof can comprise any number of contiguous amino acid residues from a polypeptide of the present invention, wherein that number is selected from the group of integers consisting of from 10 to the number of residues in a full-length hLTBP-3 polypeptide. Optionally, this subsequence of contiguous amino acids is at least 15, 20, 25, 30, 35, or 40 amino acids in length, often at least 50, 60, 70, 80, or 90 amino acids in length. Further, the number of such subsequences can be any integer selected from the group consisting of from 1 to 20, such as 2, 3, 4, or 5.

As those of skill will appreciate, the present invention includes biologically active polypeptides of the present

invention (i.e., enzymes). Biologically active polypeptides have a specific activity at least 20%, 30%, or 40%, and preferably at least 50%, 60%, or 70%, and most preferably at least 80%, 90%, or 95% - 100% of that of the native (non-synthetic), endogenous polypeptide. Further, the substrate specificity (k_{cat}/K_m) is optionally substantially similar to the native (non-synthetic), endogenous polypeptide. Typically, the K_m will be at least 30%, 40%, or 50%, that of the native (non-synthetic), endogenous polypeptide; and more preferably at least 60%, 70%, 80%, or 90%. Methods of assaying and quantifying measures of enzymatic activity and substrate specificity (k_{cat}/K_m), are well known to those of skill in the art.

Generally, the polypeptides of the present invention will, when presented as an immunogen, elicit production of an antibody specifically reactive to a polypeptide of the present invention encoded by a polynucleotide of the present invention as described, supra. Further, the proteins of the present invention will not bind to antisera raised against a polypeptide of the present invention which has been fully immunosorbed with the same polypeptide. Immunoassays for determining binding are well known to those of skill in the art. A preferred immunoassay is a competitive immunoassay as discussed, infra. Thus, the proteins of the present invention can be employed as immunogens for constructing antibodies immunoreactive to a protein of the present invention for such exemplary utilities as immunoassays or protein purification techniques.

A hLTBP-3 polypeptide of the present invention can include one or more amino acid substitutions, deletions or additions, either from natural mutations or human manipulation, as specified herein. Therefore, contemplated within the scope of the present invention are hLTBP-3 polypeptides with or without amino acid sequences comprising amino acid residues 180-228 of SEQ ID NO: 6 and/or 1-41 of

SEQ ID NO: 5 or fragments thereof.

Of course, the number of amino acid substitutions a skilled artisan would make depends on many factors, including those described above. Generally speaking, the
5 number of amino acid substitutions for any given hLTBP-3 polypeptide will not be more than 20, 10, 5, or 3, such as 1-20 or any range or value therein, as specified herein.

Amino acids in a hLTBP-3 polypeptide of the present invention that are essential for function can be identified
10 by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, Science 244:1081-1085 (1989)). The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested
15 for biological activity. Sites that are critical for ligand-protein binding can also be identified by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith et al., J. Mol. Biol. 224:899-904 (1992) and de Vos et al. Science 255:306-312
20 (1992)).

hLTBP-3 polypeptides of the present invention can include, but are not limited to, at least one domain selected from the signal peptide and active site domains of
SEQ ID NOS:2, 4, 5, or 6.

25 A hLTBP-3 polypeptide can further comprise a polypeptide encoded by 1-2000 contiguous amino acids of SEQ ID NOS:2, 4, or 6.

A hLTBP-3 polypeptide can further comprise a polypeptide encoded by 1-2000 contiguous amino acids of SEQ
30 ID NOS:2, 4, or 6 wherein said polypeptide is fused to a signal peptide including, but not limited to, the signal peptide shown as SEQ ID NO:5.

Non-limiting mutants that can enhance, decrease, or maintain at least one of the listed activities include, but
35 are not limited to, any of the above polypeptides, further comprising at least one mutation corresponding to at least one substitution selected from the group consisting of 66A,

104A, 106T, 108A, 112S, 117W, 118P, 120D, 121R, 123M, 127P,
136E, 225P, 234P, 290V, 323N, 324V, 325C, 349L, 350A, 351A,
370T, 404A, 458R, 462L, 473M, 475P, 493S, 495P, 548Q, 554S,
562A, 588K, 659I, 671T, 708S, 711T, 725Y, 760T, 782R, 813L,
5 930V, 957I, 961A, 1084T, 1094T, 1097Q, 1119S, and 1201T
corresponding to the amino acids as presented in SEQ ID NO:
2 or selected from the group consisting of 274P, 283P, 339V,
372N, 373V, 374C, 398L, 399A, 400A, 419T, 453A, 507R, 511L,
522M, 524P, 542S, 544P, 597Q, 603S, 611A, 637K, 708I, 720T,
10 757S, 760T, 774Y, 809T, 831R, 862L, 979V, 1,006I, 1010A,
1133T, 1143T, 1146Q, 1168S, and 1250T corresponding to the
amino acids as presented in SEQ ID NO: 6.

Also contemplated by the present invention are proteins
that are functionally related to hLTBP-3. For example,
15 proteins that are functionally related to SEQ ID NO: 2, 4, or
6 may be produced by conservative amino acid substitutions,
replacements, deletions, or insertions, at one or more amino
acid positions within hLTBP-3, in accordance with the Table
presented herein.

20 Modifications of hLTBP-3 polypeptides made in
accordance with the Table are generally expected to retain
the biological activity of the parent molecule based on art
recognized substitutability of the amino acids specified in
the Table (See e.g. M. Dayhoff, In Atlas of Protein Sequence
25 and Structure, Vol. 5, Supp. 3, pgs 345-352, 1978). hLTBP-3
functionality is easily tested, for example, in an assay
that measures the ability to inhibit cell proliferation.

<u>ORIGINAL RESIDUE</u>	<u>EXEMPLARY SUBSTITUTIONS</u>
ALA	SER, THR
ARG	LYS
ASN	HIS, SER
ASP	GLU, ASN
CYS	SER
GLN	ASN, HIS
GLU	ASP, GLU
GLY	ALA, SER
HIS	ASN, GLN
ILE	LEU, VAL, THR
LEU	ILE, VAL
LYS	ARG, GLN, GLU, THR
MET	LEU, ILE, VAL
PHE	LEU, TYR
SER	THR, ALA, ASN
THR	SER, ALA
TRP	ARG, SER
TYR	PHE
VAL	ILE, LEU, ALA
PRO	ALA

Fragments of proteins

One embodiment of the instant invention provides fragments of the hLTBP-3 polypeptide that may or may not be biologically active. Such fragments are useful, for example, as an antigen for producing an antibody to said protein.

Fragments of the protein disclosed herein may be generated by any number of suitable techniques, including chemical synthesis of any portion of hLTBP-3 (e.g. SEQ ID NOS: 2, 4, 5, or 6), proteolytic digestion of said proteins, or most preferably, by recombinant DNA mutagenesis techniques, well known to the skilled artisan. See. e.g. K. Struhl, "Reverse biochemistry: Methods and applications for synthesizing yeast proteins *in vitro*," *Meth. Enzymol.* 194,

520-535. For example, in a preferred method, a nested set of deletion mutations are introduced into a gene encoding hLTBP-3 (e.g. SEQ ID NOS: 1 or 3), or gene fragment thereof such that varying amounts of the protein coding region are
5 deleted, either from the amino terminal end, or from the carboxyl end of the protein molecule. This method can also be used to create internal fragments of the intact protein in which both carboxyl and amino terminal ends are removed. Several appropriate nucleases can be used to create such
10 deletions, for example *Bal31*, or in the case of a single stranded nucleic acid molecule, mung bean nuclease. For simplicity, it is preferred that the hLTBP-3 gene be cloned into a single-stranded cloning vector, such as bacteriophage M13, or equivalent. If desired, the resulting deletion
15 fragments can be subcloned into any suitable vector for propagation and expression in any suitable host cell.

Functional fragments of the hLTBP-3 polypeptide of this invention may be produced as described above, preferably using cloning techniques to engineer smaller
20 versions of the hLTBP-3 gene, lacking sequence from the 5' end, the 3' end, from both ends, or from an internal site. Smaller fragments of the genes or gene fragments of this invention can be used as a template to produce the encoded proteins. Biological function can be tested using any
25 suitable assay to measure, for example, the ability to modify cell proliferation *in vivo* or *in vitro*. For example, hLTBP-3 can be used to block the TGF- β -mediated inhibition of Mv1Lu cells or primary hepatocyte growth *in vitro* as monitored by ^3H -thymidine uptake, essentially as described
30 in Bottinger, E. P. et al., *Proc. Nat. Acad. Sci.*, 93: 5877-5882 (1996).

Gene Isolation Procedures

Those skilled in the art will recognize that the hLTBP-3 gene could be obtained by a plurality of recombinant DNA
35 techniques including, for example, hybridization, polymerase

chain reaction (PCR) amplification, or *de novo* DNA synthesis. (See e.g., T. Maniatis *et al.* Molecular Cloning: A Laboratory Manual, 2d Ed. Chap. 18 (1989)).

5 Methods for constructing cDNA libraries in a suitable vector such as a plasmid or phage for propagation in procaryotic or eucaryotic cells are well known to those skilled in the art. [See e.g. Maniatis *et al.* *Supra*]. Suitable cloning vectors are well known and are widely available.

10 The hLTBP-3 gene, or fragments thereof, can be isolated from any tissue in which said gene is expressed. For example, hLTBP-3 (SEQ ID NOS: 2 or 6) is expressed in at least one of the following tissues including brain, kidney, and spleen.

15 In one method for gene isolation, mRNA is isolated from a suitable tissue that expresses hLTBP-3, and first strand cDNA synthesis is carried out. Second round DNA synthesis can be carried out for the production of the second strand. If desired, the double-stranded cDNA can be cloned into any
20 suitable vector, for example, a plasmid, thereby forming a cDNA library. Oligonucleotide primers targeted to any suitable region of the sequences disclosed herein can be used for PCR amplification of hLTBP-3 genes. See e.g. PCR Protocols: A Guide to Method and Application, Ed. M. Innis
25 *et al.*, Academic Press (1990). The PCR amplification comprises template DNA, suitable enzymes, primers, and buffers, and is conveniently carried out in a DNA Thermal Cycler (Perkin Elmer Cetus, Norwalk, CT). A positive result is determined by detecting an appropriately-sized DNA
30 fragment following agarose gel electrophoresis.

Protein Production Methods

One embodiment of the present invention relates to substantially purified proteins encoded by the hLTBP-3
35 genes.

Skilled artisans will recognize that the proteins of the present invention can be synthesized by a number of

different methods, such as chemical methods well known in the art, including solid phase protein synthesis or recombinant methods. Both methods are described in U.S. Patent 4,617,189, incorporated herein by reference.

5 The principles of solid phase chemical synthesis of polyproteins are well known in the art and may be found in general texts in the area. See, e.g., H. Dugas and C. Penney, Bioorganic Chemistry (1981) Springer-Verlag, New York, 54-92. For example, proteins may be synthesized by
10 solid-phase methodology utilizing an Applied Biosystems 430A protein synthesizer (Applied Biosystems, Foster City, CA) and synthesis cycles supplied by Applied Biosystems.

 The proteins of the present invention can also be produced by recombinant DNA methods using a cloned or other
15 hLTBP-3 nucleic acid template. Recombinant methods are preferred if a high yield is desired. Expression of an hLTBP-3 gene can be carried out in a variety of suitable host cells, well known to those skilled in the art. For example, the hLTBP-3 gene or fragment thereof (e.g. SEQ ID
20 NOS: 1 or 3) is introduced into a host cell by any suitable means, well known to those skilled in the art. While chromosomal integration of the cloned gene is within the scope of the present invention, it is preferred that the gene or fragment thereof be cloned into a suitable extra-
25 chromosomally maintained expression vector so that the coding region of the hLTBP-3 gene is operably-linked to a constitutive or inducible promoter.

 The basic steps in the recombinant production of an hLTBP-3 polypeptide are:

- 30 a) constructing a natural, synthetic or semi-synthetic DNA encoding an hLTBP-3 polypeptide;
- b) integrating said DNA into an expression vector in a manner suitable for expressing
35 the hLTBP-3 polypeptide, either alone or as a fusion protein;

- 5 c) transforming or otherwise introducing said vector into an appropriate eucaryotic or prokaryotic cells forming a recombinant host cell;
- d) culturing said recombinant host cell in a manner to express the hLTBP-3 polypeptide; and
- 10 e) recovering and substantially purifying the hLTBP-3 polypeptide by any suitable means, well known to those skilled in the art.

Expressing Recombinant hLTBP-3 polypeptide in Procaryotic and Eucaryotic Host Cells

15 Procaryotes may be employed in the production of recombinant hLTBP-3 polypeptide. For example, the *Escherichia coli* K12 strain 294 (ATCC No. 31846) is particularly useful for the prokaryotic expression of foreign proteins. Other strains of *E. coli*, bacilli such as

20 *Bacillus subtilis*, enterobacteriaceae such as *Salmonella typhimurium* or *Serratia marcescens*, various *Pseudomonas* species and other bacteria, such as *Streptomyces*, may also be employed as host cells in the cloning and expression of the recombinant proteins of this invention.

25 Promoter sequences suitable for driving the expression of genes in procaryotes include β -lactamase [e.g. vector pGX2907, ATCC 39344, contains a replicon and β -lactamase gene], lactose systems [Chang et al., *Nature* (London), 275:615 (1978); Goeddel et al., *Nature* (London), 281:544

30 (1979)], alkaline phosphatase, and the tryptophan (trp) promoter system [vector pATH1 (ATCC 37695)], which is designed to facilitate expression of an open reading frame as a trpE fusion protein under the control of the trp promoter. Hybrid promoters such as the tac promoter

35 (isolatable from plasmid pDR540, ATCC-37282) are also suitable. Still other bacterial promoters, whose nucleotide

sequences are generally known, may be ligated to DNA encoding the protein of the instant invention, using linkers or adapters to supply any required restriction sites. Promoters for use in bacterial systems also will contain a Shine-Dalgarno sequence operably-linked to the DNA encoding the desired polyproteins. These examples are illustrative rather than limiting.

The proteins of this invention may be synthesized either by direct expression or as a fusion protein comprising the protein of interest as a translational fusion with another protein or proteins, for example, a glutathione-S-transferase (GST)-hLTBP-3 fusion protein, essentially as described in Smith & Johnson, *Gene*, 67, 31, 1988, herein incorporated by reference. Fusion partners can be removed by enzymatic or chemical cleavage. It is often observed in the production of certain proteins in recombinant systems that expression as a fusion protein prolongs the lifespan, increases the yield of the desired protein, or provides a convenient means of purifying the protein. This is particularly relevant when expressing mammalian proteins in procaryotic hosts. A variety of peptidases (e.g. enterokinase and thrombin) which cleave a polyprotein at specific sites or digest the proteins from the amino or carboxy termini (e.g. diaminopeptidase) of the protein chain are known. Furthermore, particular chemicals (e.g. cyanogen bromide) will cleave a polyprotein chain at specific sites. The skilled artisan will appreciate the modifications necessary to the amino acid sequence (and synthetic or semi-synthetic coding sequence if recombinant means are employed) to incorporate site-specific internal cleavage sites. See e.g., P. Carter, "Site Specific Proteolysis of Fusion Proteins", Chapter 13, in Protein Purification: From Molecular Mechanisms to Large Scale Processes, American Chemical Society, Washington, D.C. (1990).

In addition to procaryotes, a variety of amphibian expression systems such as frog oocytes, and mammalian cell

systems can be used. The choice of a particular host cell depends to some extent on the particular expression vector used. Exemplary mammalian host cells suitable for use in the present invention include HepG-2 (ATCC HB 8065), CV-1
5 (ATCC CCL 70), LC-MK₂ (ATCC CCL 7.1), 3T3 (ATCC CCL 92), CHO-K1 (ATCC CCL 61), HeLa (ATCC CCL 2), RPMI8226 (ATCC CCL 155), H4IIEC3 (ATCC CCL 1600), C127I (ATCC CCL 1616), HS-Sultan (ATCC CCL 1884), and BHK-21 (ATCC CCL 10), for example.

10 A wide variety of vectors are suitable for transforming mammalian host cells. For example, the pSV2-type vectors comprise segments of the simian virus 40 (SV40) genome required for transcription and polyadenylation. A large number of plasmid pSV2-type vectors have been constructed,
15 such as pSV2-gpt, pSV2-neo, pSV2-dhfr, pSV2-hyg, and pSV2- β -globin, in which the SV40 promoter drives transcription of an inserted gene. These vectors are widely available from sources such as the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland, 20852, or the
20 Northern Regional Research Laboratory (NRRL), 1815 N. University Street, Peoria, Illinois, 61604.

Promoters suitable for expression in mammalian cells include the SV40 late promoter, promoters from eukaryotic genes, such as, for example, the estrogen-inducible chicken
25 ovalbumin gene, the interferon genes, the glucocorticoid-inducible tyrosine aminotransferase gene, the thymidine kinase gene promoter, and the promoters of the major early and late adenovirus genes.

Plasmid pRSVcat (ATCC 37152) comprises portions of a
30 long terminal repeat of the Rous Sarcoma virus, a virus known to infect chickens and other host cells. This long terminal repeat contains a promoter which is suitable for use in the vectors of this invention. H. German et al., *Proc. Nat. Acad. SCI. (USA)*, 79, 6777 (1982). The plasmid
35 pMSVi (NRRL B-15929) comprises the long terminal repeats of the Murine Sarcoma virus, a virus known to infect mouse and

other host cells. The mouse metallothionein promoter has also been well characterized for use in eukaryotic host cells and is suitable for use in the present invention. This promoter is present in the plasmid p δ BPV-MMTneo (ATCC
5 37224) which can serve as the starting material for the construction of other plasmids of the present invention.

Transfection of mammalian cells with vectors can be performed by a plurality of well known processes including, but not limited to, protoplast fusion, calcium phosphate co-
10 precipitation, electroporation and the like. See, e.g., Maniatis et al., supra.

Some viruses also make appropriate vectors. Examples include the adenoviruses, the adeno-associated viruses, the vaccinia virus, the herpes viruses, the baculoviruses, and
15 the rous sarcoma virus, as described in U.S. Patent 4,775,624, incorporated herein by reference.

Eucaryotic microorganisms such as yeast and other fungi are also suitable host cells. The yeast *Saccharomyces cerevisiae* is the preferred eucaryotic microorganism. Other
20 yeasts such as *Kluyveromyces lactis* and *Pichia pastoris* are also suitable. For expression in *Saccharomyces*, the plasmid YRp7 (ATCC-40053), for example, may be used. See, e.g., L. Stinchcomb et al., *Nature*, 282, 39 (1979); J. Kingsman et al., *Gene*, 7, 181 (1979); S. Tschemper et al., *Gene*, 10, 157
25 (1980). Plasmid YRp7 contains the TRP1 gene which provides a selectable marker for use in a trp1 auxotrophic mutant.

Purification of Recombinantly-Produced hLTBP-3 polypeptides

An expression vector carrying a cloned hLTBP-3 gene or
30 fragment thereof (e.g. SEQ ID NO: 1 or 3) is transformed or transfected into a suitable host cell using standard methods. Cells that contain the vector are propagated under conditions suitable for expression of a recombinant hLTBP-3 polypeptide. For example, if the recombinant gene or
35 fragment thereof has been placed under the control of an inducible promoter, suitable growth conditions would incorporate the appropriate inducer. The recombinantly-

produced protein may be purified from cellular extracts of transformed cells by any suitable means.

In a suitable process for protein purification, an hLTBP-3 gene or fragment thereof is modified at the 5' end to incorporate several histidine codons. This modification produces an "histidine tag" at the amino terminus of the encoded protein, that enables a single-step protein purification method [i.e. "immobilized metal ion affinity chromatography" (IMAC)], essentially as described in U.S. Patent 4,569,794, which hereby is incorporated by reference. The IMAC method enables rapid isolation of substantially pure recombinant hLTBP-3 polypeptide starting from a crude extract of cells that express a modified recombinant protein, as described above.

15 Production of Antibodies

The proteins of this invention and fragments thereof may be used in the production of antibodies. The instant invention also encompasses single-chain polypeptide binding molecules.

20 The production of antibodies, both monoclonal and polyclonal, in animals, especially mice, is well known in the art. See, e.g., C. Milstein, Handbook of Experimental Immunology, (Blackwell Scientific Pub., 1986); J. Goding, Monoclonal Antibodies: Principles and Practice, (Academic Press, 1983). For the production of monoclonal antibodies the basic process begins with injecting a mouse, or other suitable animal, with an immunogen. The mouse is subsequently sacrificed and cells taken from its spleen are fused with myeloma cells, resulting in a hybridoma that reproduces *in vitro*. The population of hybridomas is screened to isolate individual clones, each of which secretes a single antibody species, specific for the immunogen. Each antibody obtained in this way is the clonal product of a single B cell.

35 Chimeric antibodies are described in U.S. Patent No. 4,816,567, the entire contents of which is herein incorporated by reference. This reference discloses methods

and vectors for the preparation of chimeric antibodies. An alternative approach is provided in U.S. Patent No. 4,816,397, the entire contents of which is herein incorporated by reference. This patent teaches co-expression of the heavy and light chains of an antibody in the same host cell.

The approach of U.S. Patent 4,816,397 has been further refined in European Patent Publication No. 0 239 400. The teachings of this European patent publication are a preferred format for genetic engineering of monoclonal antibodies. In this technology the complementarity determining regions (CDRs) of a human antibody are replaced with the CDRs of a murine monoclonal antibody, thereby converting the specificity of the human antibody to the specificity of a murine antibody.

Single chain antibodies and libraries thereof are yet another variety of genetically engineered antibody technology that is well known in the art. (See, e.g. R.E. Bird, et al., *Science* 242:423-426 (1988); PCT Publication Nos. WO 88/01649, WO 90/18430, and WO 91/10737. Single chain antibody technology involves covalently joining the binding regions of heavy and light chains to generate a single polypeptide chain. The binding specificity of the intact antibody molecule is thereby reproduced on a single polypeptide chain.

The antibodies contemplated by this invention are useful in diagnostics, therapeutics or in combinations thereof.

The proteins of this invention or suitable fragments thereof can be used to generate polyclonal or monoclonal antibodies, and various inter-species hybrids, or humanized antibodies, or antibody fragments, or single-chain antibodies. The techniques for producing antibodies are well known to skilled artisans. (See e.g. A.M. Campbell, Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers, Amsterdam (1984); Kohler and Milstein, *Nature*

256, 495-497 (1975); Monoclonal Antibodies: Principles & Applications Ed. J.R.Birch & E.S. Lennox, Wiley-Liss, 1995.

A protein used as an immunogen may be modified or administered in an adjuvant, by subcutaneous or
5 intraperitoneal injection into, for example, a mouse or a rabbit. For the production of monoclonal antibodies, spleen cells from immunized animals are removed, fused with myeloma cells, such as SP2/0-Ag18 cells, and allowed to become monoclonal antibody producing hybridoma cells in the manner
10 known to the skilled artisan. Hybridomas that secrete a desired antibody molecule can be screened by a variety of well known methods, for example ELISA assay, western blot analysis, or radioimmunoassay (Lutz et al. *Exp. Cell Res.* 175, 109-124 (1988); Monoclonal Antibodies: Principles &
15 Applications Ed. J.R.Birch & E.S. Lennox, Wiley-Liss, 1995).

For some applications labeled antibodies are desirable. Procedures for labeling antibody molecules are widely known, including for example, the use of radioisotopes, affinity labels, such as biotin or avidin, enzymatic labels, for
20 example horseradish peroxidase, and fluorescent labels, such as FITC or rhodamine (See e.g. Enzyme-Mediated Immunoassay, Ed. T. Ngo, H. Lenhoff, Plenum Press 1985; Principles of Immunology and Immunodiagnostics, R.M. Aloisi, Lea & Febiger, 1988).

25 Labeled antibodies are useful for a variety of diagnostic applications. In one embodiment the present invention relates to the use of labeled antibodies to detect the presence of hLTBP-3 polypeptides. Alternatively, the antibodies could be used in a screen to identify potential
30 modulators of hLTBP-3. For example, in a competitive displacement assay, the antibody or compound to be tested is labeled by any suitable method. Competitive displacement of an antibody from an antibody-antigen complex by a test compound such that a test compound-antigen complex is formed
35 provides a method for identifying compounds that bind hLTBP-3.

Other embodiments of the present invention comprise isolated nucleic acid sequences that encode the proteins of the invention, for example, SEQ ID NO: 1. Also contemplated are related nucleic acids that hybridize to SEQ ID NO: 1,
5 SEQ ID NO: 2, or related fragments thereof, e.g. under high stringency conditions. Such sequences may come, for example, from paralogous or orthologous genes.

The nucleic acids of the invention (e.g. SEQ ID NOS: 1 and 3) and related nucleic acid molecules may be produced by
10 chemical synthetic methods. The synthesis of nucleic acids is well known in the art. See, e.g., E.L. Brown, R. Belagaje, M.J. Ryan, and H.G. Khorana, *Methods in Enzymology*, 68:109-151 (1979). Nucleic acids of this invention, including those disclosed herein, could be
15 generated using a conventional DNA synthesizing apparatus, such as the Applied Biosystems Model 380A or 380B DNA synthesizers (Applied Biosystems, Inc., 850 Lincoln Center Drive, Foster City, CA 94404) using phosphoramidite chemistry, thereafter ligating the fragments so as to
20 reconstitute the entire gene. Alternatively, phosphotriester chemistry may be employed to synthesize the nucleic acids of this invention. (See, e.g., M.J. Gait, ed., Oligonucleotide Synthesis, A Practical Approach, (1984)).

25 In an alternative methodology, namely PCR, the DNA sequences disclosed and described herein, can be produced from a plurality of starting materials. For example, starting with a cDNA preparation (e.g. cDNA library) derived from a tissue that expresses an hLTBP-3 gene, suitable
30 oligonucleotide primers complementary to, for example, SEQ ID NO: 1, SEQ ID NO: 3, or to a sub-region therein, for example, are prepared as described in U.S. Patent No. 4,889,818, hereby incorporated by reference. Other suitable protocols for the PCR are disclosed in PCR Protocols: A
35 Guide to Method and Applications, Ed. Michael A. Innis et al., Academic Press, Inc. (1990). Using PCR, any region of

the hLTBP-3 gene(s) can be targeted for amplification such that full or partial length gene sequences may be produced.

The ribonucleic acids of the present invention may be prepared using polynucleotide synthetic methods discussed
5 *supra*, or they may be prepared enzymatically, for example, using RNA polymerase to transcribe a hLTBP-3 DNA template.

The most preferred systems for preparing the ribonucleic acids of the present invention employ the RNA polymerase from the bacteriophage T7 or the bacteriophage
10 SP6. These RNA polymerases are highly specific, requiring the insertion of bacteriophage-specific sequences at the 5' end of the template to be transcribed. See, Maniatis *et al.*, *supra*.

This invention also provides nucleic acids, RNA or DNA,
15 that are complementary to the hLTBP-3 polynucleotides as shown in SEQ ID NOS: 1 or 3 as well as fragments thereof.

Nucleic Acid Probes

The present invention also provides probes and primers useful, for example, in hybridization screens of genomic,
20 subgenomic, or cDNA libraries, as well as hybridization against nucleic acids derived from cell lines or tissues. Such hybridization screens are useful as methods to identify and isolate full length, or identical, homologous or functionally related sequences from human or other
25 organisms.

In one embodiment the present invention relates to the use of a nucleic acid disclosed herein as a probe to identify and isolate full-length genes comprising said nucleic acids. A nucleic acid compound comprising SEQ ID NO:
30 1, SEQ ID NO: 3, a complementary sequence thereof, or a fragment thereof, which is at least 14 base pairs in length, and which will selectively hybridize to DNA or mRNA encoding hLTBP-3 polypeptide or fragment thereof, or a functionally related protein, is provided. Preferably, the 14 or more
35 base pair compound is DNA. See e.g. B. Wallace and G. Miyada, "Oligonucleotide Probes for the Screening of

Recombinant DNA Libraries," In *Meth. Enzym.*, 152, 432-442, Academic Press (1987).

Probes and primers can be prepared by enzymatic or recombinant methods, well known to those skilled in the art (See e.g. Sambrook et al. *supra*). A probe may be a single stranded nucleic acid sequence which is complementary in some particular degree to a nucleic acid sequence sought to be detected ("target sequence"). A probe may be labeled with a detectable moiety such as a radio-isotope, antigen, or chemiluminescent moiety. A description of the use of nucleic acid hybridization as a procedure for the detection of particular nucleic acid sequences is described in U.S. Patent No. 4,851,330 to Kohne, entitled "Method for Detection, Identification and Quantitation of Non-Viral Organisms."

Having the DNA sequence of the present invention allows preparation of relatively short DNA (or RNA) sequences having the ability to specifically hybridize to nucleic acids that are homologous or identical to sequences disclosed herein. In these aspects, nucleic acid probes of an appropriate length are prepared. The ability of such nucleic acid probes to specifically hybridize to a polynucleotide encoding a hLTBP-3 gene or related sequence lends particular utility in a variety of embodiments. Most importantly, the probes may be used in a variety of assays for detecting the presence of complementary sequences in a given sample.

In certain embodiments, it is advantageous to use oligonucleotide primers. The sequence of such primers is designed using a polynucleotide of the present invention for use in detecting, amplifying or mutating a defined segment of a gene or polynucleotide that encodes an hLTBP-3 polyprotein, using PCR technology.

Preferred nucleic acid sequences employed for hybridization studies, or assays, include probe molecules that are complementary to at least an about

18 to an about 70-nucleotide long stretch of a polynucleotide that encodes an hLTBP-3 polyprotein. Molecules having complementary sequences over stretches greater than 18 bases in length are generally preferred, in order to increase stability and selectivity of the hybrid. One will generally prefer to design nucleic acid molecules having gene-complementary stretches of 25 to 40 nucleotides, 55 to 70 nucleotides, or even longer where desired. Such fragments may be readily prepared by, for example, directly synthesizing the fragment by chemical means, by application of nucleic acid reproduction technology, such as the PCR TM technology of U.S. Pat. No. 4,603,102, herein incorporated by reference, or by excising selected DNA fragments from recombinant plasmids containing appropriate inserts and suitable restriction enzyme sites.

The following guidelines are useful for designing probes with desirable characteristics. The extent and specificity of hybridization reactions are affected by a number of factors that determine the sensitivity and specificity of a particular probe, whether perfectly complementary to its target or not. The affect of various experimental parameters and conditions are well known to those skilled in the art.

First, the stability of the probe:target nucleic acid hybrid should be chosen to be compatible with the assay conditions. This may be accomplished by avoiding long A and T rich sequences, by terminating the hybrids with G:C base pairs and by designing a probe with an appropriate T_m (i.e. melting temperature). The melting profile, including the T_m of a hybrid comprising an oligonucleotide and target sequence, may be determined using a Hybridization Protection Assay. The probe should be chosen so that the length and % GC content result in a T_m about 2°-10° C higher than the temperature at which the final assay will be performed. The base composition of the probe is also a significant factor because G-C base pairs exhibit greater thermal stability as compared to A-T base pairs. Thus, hybridization involving

complementary nucleic acids of higher G-C content will be more stable at higher temperatures.

The ionic strength and incubation temperature under which a probe will be used should also be taken into
5 account. It is known that hybridization will increase as the ionic strength of the reaction mixture increases, and that the thermal stability of molecular hybrids will increase with increasing ionic strength. On the other hand, chemical
10 reagents such as formamide, urea, DMSO and alcohols, which disrupt hydrogen bonds, increase the stringency of hybridization. Destabilization of hydrogen bonds by such reagents can greatly reduce the T_m . In general, optimal hybridization for synthetic oligonucleotide probes of about
15 10-50 bases in length occurs approximately 5° C below the melting temperature for a given duplex. Incubation at temperatures below the optimum may allow mismatched base sequences to hybridize and can therefore result in reduced specificity.

The length of the target nucleic acid sequence and,
20 accordingly, the length of the probe sequence can also be important. In some cases, there may be several sequences from a particular region, varying in location and length, which will yield probes with the desired hybridization characteristics. In other cases, one sequence may be
25 significantly better than another even though the one sequence differs merely by a single base. Finally, there can be intramolecular and intermolecular hybrids formed within a probe if there is sufficient self-complementarity. Such structures can be avoided through careful probe design.
30 Computer programs are available to search for this type of interaction.

A probe molecule may be used for hybridizing to a sample suspected of possessing an hLTBP-3 or related nucleotide sequence. The hybridization reaction is carried
35 out under suitable conditions of stringency.

Alternatively, such DNA molecules may be used in a number of techniques including their use as: (1) diagnostic

tools to detect polymorphisms in DNA samples from a human or other mammal; (2) means for detecting and isolating homologs of hLTBP-3 and related polyproteins from a DNA library potentially containing such sequences; (3) primers for
5 hybridizing to related sequences for the purpose of amplifying those sequences; and (4) primers for altering the native hLTBP-3 DNA sequences; as well as other techniques which rely on the similarity of the DNA sequences to those of the hLTBP-3 DNA segments herein disclosed.

10 Once synthesized, oligonucleotide probes may be labeled by any of several well known methods. See e.g. Maniatis et.al., Molecular Cloning (2d ed. 1989). Useful labels include radioisotopes, as well as non-radioactive reporting groups. Isotopic labels include H³, S³⁵, P³², I¹²⁵, Cobalt, and
15 C¹⁸. Most methods of isotopic labeling involve the use of enzymes and include methods such as nick-translation, end-labeling, second strand synthesis, and reverse transcription. When using radio-labeled probes, hybridization can be detected by autoradiography,
20 scintillation counting, or gamma counting. The detection method selected will depend upon the hybridization conditions and the particular radio isotope used for labeling.

Non-isotopic materials can also be used for labeling,
25 and may be introduced internally into the sequence or at the end of the sequence. Modified nucleotides may be incorporated enzymatically or chemically, and chemical modifications of the probe may be performed during or after synthesis of the probe, for example, by the use of non-
30 nucleotide linker groups. Non-isotopic labels include fluorescent molecules, chemiluminescent molecules, enzymes, cofactors, enzyme substrates, haptens or other ligands. In a preferred embodiment of the invention, the length of an oligonucleotide probe is greater than or equal to about 18
35 nucleotides and less than or equal to about 50 nucleotides. Labeling of an oligonucleotide of the present invention may

be performed enzymatically using [³²P]-labeled ATP and the enzyme T4 polynucleotide kinase.

Vectors

5 Another aspect of the present invention relates to recombinant DNA cloning vectors and expression vectors comprising the nucleic acids of the present invention. The preferred nucleic acid vectors are those which comprise DNA, for example, SEQ ID NOS: 1 or 3 or a subregion therein.

10 The skilled artisan understands that choosing the most appropriate cloning vector or expression vector depends upon a number of factors including the availability of restriction enzyme sites, the type of host cell into which the vector is to be transfected or transformed, the purpose

15 of the transfection or transformation (e.g., stable transformation as an extrachromosomal element, or integration into the host chromosome), the presence or absence of readily assayable or selectable markers (e.g., antibiotic resistance and metabolic markers of one type and

20 another), and the number of copies of the gene desired in the host cell.

Vectors suitable to carry the nucleic acids of the present invention comprise RNA viruses, DNA viruses, lytic bacteriophages, lysogenic bacteriophages, stable

25 bacteriophages, plasmids, viroids, and the like. The most preferred vectors are plasmids.

When preparing an expression vector the skilled artisan understands that there are many variables to be considered, for example, whether to use a constitutive or inducible

30 promoter. The practitioner also understands that the amount of nucleic acid or protein to be produced dictates, in part, the selection of the expression system. Regarding promoter sequences, inducible promoters are preferred because they enable high level, regulatable expression of an operably-

35 linked gene. The skilled artisan will recognize a number of suitable promoters that respond to a variety of inducers, for example, carbon source, metal ions, and heat. Other

relevant considerations regarding an expression vector include whether to include sequences for directing the localization of a recombinant protein. For example, a sequence encoding a signal protein (e.g., SEQ ID NO: 5) preceding the coding region of a gene is useful for directing the extra-cellular export of a resulting polypeptide.

The present invention also provides a method for constructing a recombinant host cell capable of expressing the proteins of the invention, said method comprising transforming or otherwise introducing into a host cell a recombinant DNA vector that comprises an isolated DNA sequence that encodes a protein of this invention. A suitable host cell is any eucaryotic cell that can accommodate high level expression of an exogenously introduced gene or protein, and that will incorporate said protein into its membrane structure. Vectors for expression are those which comprise an hLTBP-3 polynucleotide as shown in SEQ ID NOS: 1 or 3, as well as any suitable subregion therein. Transformed host cells may be cultured under conditions well known to skilled artisans such that a protein of the present invention is expressed, thereby producing a recombinant hLTBP-3 polypeptide in the recombinant host cell.

For the purpose of identifying compounds having utility as modifiers, agonists, and/or antagonists of cell proliferation, it would be desirable to identify compounds that bind an hLTBP-3 polypeptide of the present invention, and/or modify its activity. A method for determining agents that bind the hLTBP-3 polypeptide and/or activate or inhibit its activity, comprises contacting the hLTBP-3 polypeptide with a test compound and monitoring binding by any suitable means.

The instant invention provides a screening system for discovering compounds that bind the hLTBP-3 polypeptide, said screening system comprising the steps of:

- a) preparing an hLTBP-3 polypeptide by any means known to one skilled in the art;
- b) exposing said hLTBP-3 polypeptide to a test compound;
- 5 c) quantifying the binding of said compound to hLTBP-3 polypeptide by any suitable means, for example, by monitoring the spectroscopic changes in intrinsic tryptophan fluorescence of hLTBP-3
- 10 induced by the binding of the compound (Winzor, D.J and Sawyer, W.H., Quantitative Characterization of Ligand Binding. Wiley-Liss, NY. 1995).

Utilization of the screening system described above

15 provides a means to identify compounds that may alter, augment, or inhibit the biological function of hLTBP-3 polypeptides. This screening method may be adapted to large-scale, automated procedures such as a PANDEX® (Baxter-Dade Diagnostics) system, allowing for efficient high-volume

20 screening for potential therapeutic agents.

In one embodiment of this aspect of the invention, hLTBP-3 is prepared as described herein, preferably using recombinant DNA technology. A test compound is introduced into a reaction vessel containing an hLTBP-3 polypeptide or

25 fragment thereof. Binding of hLTBP-3 by a test compound is determined by any suitable means. For example, in one method radioactively- labeled or chemically-labeled test compound may be used. Binding of the protein by the test compound is assessed, for example, by quantifying bound label versus

30 unbound label using any suitable method.

Binding of a test compound may also be carried out by a method disclosed in U.S. Patent 5,585,277, which hereby is incorporated by reference. In this method, binding of a test compound to a protein is assessed by monitoring the ratio of

35 folded protein to unfolded protein, for example, by

monitoring sensitivity of said protein to a protease, or amenability for binding of said protein by a specific antibody against the folded state of the protein.

The foregoing screening methods are useful for identifying an agonist and/or antagonist of a hLTBP-3 polypeptide as a lead to a pharmaceutical compound for treating cancer. For example, a compound that binds hLTBP-3, or related fragment thereof, is identified by combining a test compound with hLTBP-3 under conditions that cause the protein to exist in a ratio of folded to unfolded states. If a test compound binds the folded state of the protein, the relative amount of folded protein will be higher than in the case of a test compound that does not bind the protein. The ratio of protein in the folded versus unfolded state is easily determinable by, for example, susceptibility to digestion by a protease, or binding to a specific antibody, or binding to chaperonin protein, or binding to any suitable surface.

In addition, use of antagonists of TGF β may form the basis of important novel approaches for the treatment of a large spectrum of serious chronic conditions in which excessive TGF β action appears to be responsible for tissue damage caused by scarring (Border and Noble, 1994, N. Engl. J. Med. 331: 1286-1292; Border and Ruoslahti, 1992, J. Clin. Invest. 90: 1-7). Indeed, in previous studies, antiserum to TGF- β have been shown to protect against scarring in experimental skin lesions and kidney disease (Shah et al., 1992, Lancet, 339: 213-214; Border et al., 1992, Kidney Int. 41: 566-570). Thus, hLTBP-3 can be used as a potent and specific inhibitor of TGF- β for the prevention of fibrotic conditions.

hLTBP-3 polypeptide Therapeutic Applications

In one embodiment, the present invention relates to therapeutic applications in which the inhibition of cell proliferation is therapeutically desirable. For example,

hLTBP-3 is administered to prevent or inhibit tumor growth, or as a treatment for cancers, for example, brain, kidney, bone, or splenial cancers.

For therapeutic use in preventing or inhibiting tumor growth, or in treating cancer, an effective amount of hLTBP-3 polypeptide is administered to an organism in need thereof in a dose between about 0.1 and 1000 $\mu\text{g/kg}$ body weight. In practicing the methods contemplated, hLTBP-3 can be administered in a single daily dose or in multiple doses per day. The amount per administration will be determined by the physician and depend on such factors as the nature and severity of the disease, and the age and general health of the patient.

The present invention also provides a pharmaceutical composition comprising as the active agent a hLTBP-3 polypeptide or fragment thereof, or a pharmaceutically acceptable non-toxic salt thereof, and a pharmaceutically acceptable solid or liquid carrier. For example, compounds comprising hLTBP-3 can be admixed with conventional pharmaceutical carriers and excipients, and used in the form of tablets, capsules, elixirs, suspensions, syrups, wafers, and the like. The compositions comprising hLTBP-3 will contain from about 0.1% to 90% by weight of the active compound, and more generally from about 10% to 30%. The compositions may contain common carriers and excipients such as corn starch or gelatin, lactose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride, and alginic acid. The compounds can be formulated for oral or parenteral administration.

For intravenous (IV) use, the hLTBP-3 polypeptide is administered in commonly used intravenous fluid(s) and administered by infusion. Such fluids, for example, physiological saline, Ringer's solution or 5% dextrose solution can be used.

For intramuscular preparations, a sterile formulation, preferably a suitable soluble salt form of the hLTBP-3

polypeptide (e.g., SEQ ID NOS: 2, 4, or 6) such as the hydrochloride salt, can be dissolved and administered in a pharmaceutical diluent such as pyrogen-free water (distilled), physiological saline or 5% glucose solution. A
5 suitable insoluble form of the compound may be prepared and administered as a suspension in an aqueous base or a pharmaceutically acceptable oil base, e.g. an ester of a long chain fatty acid such as ethyl oleate.

Skilled artisans will recognize that IC₅₀ values are
10 dependent on the selectivity of the compound tested. For example, a compound with an IC₅₀ which is less than 10 nM is generally considered an excellent candidate for drug therapy. However, a compound which has a lower affinity, but is selective for a particular target, may be an even
15 better candidate. The skilled artisan will recognize that any information regarding the binding potential, inhibitory activity, or selectivity of a particular compound is useful toward the development of pharmaceutical products.

The following examples more fully describe the present
20 invention. Those skilled in the art will recognize that the particular reagents, equipment, and procedures described are merely illustrative and are not intended to limit the present invention in any manner.

25

EXAMPLE 1

RT-PCR Amplification of hLTBP-3 from mRNA

The hLTBP-3 gene is isolated by reverse transcriptase PCR (RT-PCR) using conventional methods. Total RNA is prepared from a tissue that expresses the hLTBP-3 gene, for
30 example, cartilage, bone, or spleen, using standard methods. First strand cDNA synthesis is achieved using a commercially available kit (SuperScript™ System; Life Technologies) by PCR in conjunction with appropriate primers directed at any suitable region of SEQ ID NO: 1, e.g. the 5' and 3' ends of
35 the gene, specifically at nucleotide residues 1 (5' end) and 3798 (3' end).

Amplification is carried out by adding to the first strand cDNA (dried under vacuum): 8 μ l of 10X synthesis buffer (200 mM Tris-HCl, pH 8.4; 500 mM KCl, 25 mM MgCl₂, 1 μ g/ μ l BSA); 68 μ l distilled water; 1 μ l each of a 10 μ M solution of each primer; and 1 μ l Taq DNA polymerase (2 to 5 U/ μ l). The reaction is heated at 94° C for 5 min. to denature the RNA/cDNA hybrid. Then, 15 to 30 cycles of PCR amplification are performed using any suitable thermal cycle apparatus. The amplified sample may be analyzed by agarose gel electrophoresis to check for an appropriately-sized fragment.

EXAMPLE 2

Production of a Vector for Expressing hLTBP-3 in a Host Cell

An expression vector suitable for expressing hLTBP-3 or fragment thereof in a variety of procaryotic host cells, such as *E. coli* is easily made. The vector contains an origin of replication (Ori), an ampicillin resistance gene (Amp) useful for selecting cells which have incorporated the vector following a transformation procedure, and further comprises the T7 promoter and T7 terminator sequences in operable linkage to a hLTBP-3 coding region. Plasmid pET11A (obtained from Novogen, Madison WI) is a suitable parent plasmid. pET11A is linearized by restriction with endonucleases NdeI and BamHI. Linearized pET11A is ligated to a DNA fragment bearing NdeI and BamHI sticky ends and comprising all or part of the coding region of the hLTBP-3 gene as disclosed by, for example, SEQ ID NO: 1.

The hLTBP-3 gene used in this construction may be slightly modified at the 5' end (amino terminus of encoded protein) in order to simplify purification of the encoded protein product. For this purpose, an oligonucleotide encoding 8 histidine residues is inserted at or near the 5' end of the hLTBP-3 gene, so as to maintain the correct reading frame. Placement of the histidine residues at the amino terminus of the encoded protein serves to enable the IMAC one-step protein purification procedure.

EXAMPLE 3

Recombinant Expression and Purification of hLTBP-3 polypeptide

5 An expression vector that carries a gene encoding hLTBP-3 or fragment thereof and which gene is operably-linked to an expression promoter is transformed into *E. coli* BL21 (DE3) (*hsdS gal λ cIts857 ind1Sam7nin5lacUV5-T7gene 1*) using standard methods. Transformants, selected for
10 resistance to ampicillin, are chosen at random and tested for the presence of the vector by agarose gel electrophoresis using quick plasmid preparations. Colonies which contain the vector are grown in L broth and the protein product encoded by the vector-borne gene is purified
15 by immobilized metal ion affinity chromatography (IMAC), essentially as described in US Patent 4,569,794.

Briefly, the IMAC column is prepared as follows. A metal-free chelating resin (e.g. Sepharose 6B IDA, Pharmacia) is washed in distilled water to remove
20 preservative substances and infused with a suitable metal ion [e.g. Ni(II), Co(II), or Cu(II)] by adding a 50mM metal chloride or metal sulfate aqueous solution until about 75% of the interstitial spaces of the resin are saturated with colored metal ion. The column is then ready to receive a
25 crude cellular extract containing the recombinant protein product.

After removing unbound proteins and other materials by washing the column with any suitable buffer, pH 7.5, the bound protein is eluted in any suitable buffer at pH 4.3, or
30 preferably with an imidazole-containing buffer at pH 7.5.

EXAMPLE 4

Tissue Distributuion of hLTBP-3 mRNA

hLTBP-3 mRNA is detected in a mammalian tissue by
35 Northern analysis. Total RNA from different tissues or cultured cells is isolated by a standard guanidine

chloride/phenol extraction method, and poly-A⁺ RNA is isolated using oligo(dT)-cellulose type 7 (Pharmacia). Electrophoresis of RNA samples is carried out in formaldehyde followed by capillary transfer to Zeta-Probe
5 TM nylon membranes (Bio-Rad, Hercules, Calif.). SEQ ID NO: 1 or SEQ ID NO: 3 is used as a template for generating probes using a MultiPrimeTM random priming kit (Amersham, Arlington Heights, Ill.). The efficiency of the labeling reaction is approximately 4×10^{10} cpm incorporated per μg of template.
10 The hybridization buffer contains 0.5M sodium phosphate, 7% SDS (wt/vol), 1% BSA (wt/vol), and 1 mM EDTA. Prehybridization is carried out in hybridization buffer at 65° C for 2 h, and ³²P-labeled probe is added and incubation continued overnight. Filters are washed in Buffer A (40 mM
15 sodium phosphate pH 7.2, 5% SDS [wt/vol], 0.5% BSA [wt/vol], and 1 mM EDTA) at 65° C for 1 h, then in Buffer B (40 mM sodium phosphate, pH 7.2, 1% SDS [wt/vol], and 1 mM EDTA) at 65° C for 20 min. Filters are then air-dried and exposed to Kodak X-OMAT AR film at -80° C with an intensifying screen.

20

EXAMPLE 5

Detecting Ligands that Bind hLTBP-3 Using a Protein-Interaction Assay

The wells of an ELISA plate are coated with chaperonin
25 or other proteins known to interact with hLTBP-3 by incubation for several hours with a 4 $\mu\text{g}/\text{ml}$ solution of the protein in Tris-buffered Saline (TBS: 10 mM Tris-HCl, pH7.5, 0.2M NaCl). Plates are washed 3 times with TBS containing 0.1% Tween-20 (TBST). Then, a mixture of hLTBP-3 polypeptide
30 (sufficient amount to saturate about 50% of the binding sites) and test compound (10^{-9} to 10^{-5} M) in about 50 μl volume is added to each well of the plate for an incubation of about 60 minutes. Aliquots from each well are then transferred to the wells of fresh plates and incubation is
35 continued for 60 minutes at room temperature, followed by 3 washes with TBST. Next, about 50 μl of an antibody specific

for hLTBP-3 in 5% nonfat dry milk is added to each well for 30 minutes at room temperature. After washing, about 50 μ l of goat anti-rabbit IgG alkaline phosphatase conjugate at an appropriate dilution in TBST plus 5% nonfat dry milk is added to each well and incubated 30 minutes at room temperature. The plates are washed again with TBST, and 0.1 ml of 1 mg/ml p-nitrophenylphosphate in 0.1% diethanolamine is added. Color development (proportional to bound alkaline phosphatase antibody conjugate) is monitored with an ELISA plate reader. When binding by the test ligand has occurred, ELISA analysis reveals hLTBP-3 in solution at higher concentrations than in the absence of test ligand.

EXAMPLE 6

15 Production of an Antibody to hLTBP-3 polypeptide

Substantially pure hLTBP-3 polypeptide or fragment thereof is isolated from transfected or transformed cells using any of the well known methods in the art, or by a method specifically disclosed herein. Concentration of protein is adjusted, for example, by filtration through an Amicon filter device such that the level is about 1 to 5 μ g/ml. Monoclonal or polyclonal antibody is prepared as follows.

Monoclonal antibody can be prepared from murine hybridomas according to the method of Kohler and Milstein (Nature, 256, 495, 1975), or a modified method thereof. Briefly, a mouse is repetitively inoculated with a few micrograms of the hLTBP-3 polypeptide (e.g. SEQ ID NOS:2, 4, or 6), fragment thereof, or fusion protein thereof, over a period of a few weeks. The mouse is then sacrificed, and antibody producing cells of the spleen are isolated. Spleen cells are fused with mouse myeloma cells using polyethylene glycol. Fused cells that produce antibody are identified by any suitable immunoassay, for example, ELISA, as described in E. Engvall, Meth. Enzymol., 70, 419, 1980.

Polyclonal antiserum can be prepared by well known methods (See e.g. J. Vaitukaitis et.al. *Clin. Endocrinol. Metab.* 33, 988, 1971) that involve immunizing suitable animals with a hLTBP-3 polypeptide, fragments thereof, or fusion proteins thereof. Small doses (e.g. nanogram amounts) of antigen administered at multiple intradermal sites are the most reliable method.

EXAMPLE 7

10 Cell Proliferation Assays for hLTBP-3 Activity

The effect of hLTBP-3 on reversing inhibition of cell growth induced by TGF β can be assessed in various cell lines including, but not limited to, the Mv1Lu cell line (Bottinger et al., 1996, *Proc. Natl. Acad. Sci. USA* 93: 5877-5882). Briefly, MV1Lu cells (1×10^6 cells/well in 24 well dishes) are grown in the presence of TGF- β (1-10 pM) and varying concentrations of recombinant hLTBP-3. Cell growth is monitored by [^{3} H]thymidine incorporation into cellular DNA over a 24 hour time period. Radioactivity can be measured by the scintillation proximity technique in a Wallac 1450 microbeta counter or by traditional scintillation counting.

25 EXAMPLE 8

Cell Based Assays for hLTBP-3 Activity

Transfected cell lines including, but not limited to, MV1Lu can also be employed to monitor the modulation of TGF- β activated gene expression by exogenously applied hLTBP-3. For instance, the induction of the plasminogen activator inhibitor 1 (PAI-1) promoter by TGF- β can be monitored in cells stably transfected with the PAI-1 promoter fused to a reporter gene (i.e., luciferase) (Abe, et al., 1994, *Anal. Biochem.* 216: 276-284). Stable cell lines would be incubated for 48 hours with TGF- β and varying concentration

of hLTBP-3 polypeptide. The amount of luciferase protein produced would be quantitated directly by the photons emitted by cell lysates incubated with luciferin substrate using a luminometer.

5 To elucidate its role on endothelial cell anticoagulant and profibrinolytic activities, the effects of hLTBP-3 over-expression on two well-characterized markers of endothelial cell function, thrombomodulin (TM) and plasminogen activator inhibitor-1 (PAI-1), can be examined. Both markers are known
10 to be responsive to TGF β , with TM being suppressed and PAI-1 being activated.

These experiments can also be conducted in various cell lines including, but not limited to, SVHA-1 (an SV40 transformed human aortic endothelial cell line) and ECV304 (a
15 spontaneously transformed human umbilical vein endothelial cell line) (ATCC CRL-1998). The cells are maintained in DMEM/F-12 (3:1), a medium comprised of a 3:1 v/v mixture of Dulbecco's Modified Eagle's Medium and Ham's nutrient mixture F-12. The basal medium is supplemented with 10 nM selenium,
20 50 μ M 2-aminoethanol, 20 mM HEPES, 50 μ g/ml gentamicin, and 5% fetal bovine serum (FBS).

A. PAI-1 Promoter activity

In order to determine the effects of hLTBP-3 on PAI-1
25 secretion and promoter activity, the PAI-1 basal promoter driving the expression of the CAT indicator gene (pOCAT2336) and a TGF β hyper-responsive PAI-1/TRE promoter construct (3TP-lux) driving the expression of the luciferase indicator gene are used. hLTBP-3 expressing vectors are constructed by
30 inserting the hLTBP-3 coding sequence, or fragments thereof, into any suitable expression vector such as pN8e23/3xFlu2 or any other standard expression vectors. ECV304 cells are seeded in 6-well plates to 80% confluence. DNA is transfected at a concentration of 1 μ g per well for pOCAT2336 and 3TP-lux

and 5 µg per well for the hLTBP-3 insert containing vector with lipofectin reagent (Gibco/Life Technologies, Gaithersburg, MD). Expressed CAT protein from the PAI-1 basal promoter construct was determined using a CAT ELISA kit
5 (Boehringer Mannheim; Indianapolis, IN). Chemiluminescence resulting from expression of the luciferase gene is determined as a measure of the effect on the PAI-1/TRE promoter. The plates are read kinetically and data expressed in terms of promoter activity relative to control.

10 These experiments will detect any hLTBP-3 dependent effect on the PAI-1 promoter due to the highly TGFβ-responsive transcriptional element based on the PAI-1 promoter (p3TP-Lux) as well as with the basal PAI-1 promoter (pPAI-CAT). In particular, hLTBP-3 over-expression should result in a greater
15 effect using the more TGFβ-sensitive 3TP-lux plasmid.

 In addition to the ability of hLTBP-3 over-expression to regulate the activity of artificial promoter constructs, the actual level of PAI-1 secretion from the cells can also be measured as a marker of hLTBP-3 effects on TGFβ regulated
20 activities.

B. Thrombomodulin activity

 Determination of thrombomodulin anticoagulant activity can be performed in confluent cultures of SVHA-1 cells. The cultures are washed once with Hank's Basal Salt Solution to
25 remove serum proteins and incubated with serum-free medium (DMEM/F-12 medium, 20 mM-HEPES, pH 7.5, 50 mg/ml gentamicin, 1 µg/ml human transferrin and 1 µg/ml bovine insulin) containing 400 nM recombinant human proteins (made according to techniques as set forth in U.S. Patent No. 4,981,952) and 10
30 nM human thrombin (Sigma; St. Louis, MO). Cultures are incubated at 37°C, and at various times medium is removed and added to an equal volume of a solution of 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mg/ml BSA, and 10 U/ml hirudin. The

samples are incubated in the hirudin-containing buffer for 5 minutes to inhibit thrombin activity. In all experiments, samples of the protein C/thrombin solution are incubated in wells without cells to determine basal levels of thrombin-catalyzed activation of protein C.

The amount of activated protein C generated is determined by adding chromogenic substrate (S2366) (Chromogenix, Mölndal, Sweden) to a final concentration of 0.75 mM, and measuring the change in absorbance units/minute at 405 nm in a kinetic micro-titer plate reader. Results are expressed in terms of maximal response to TGF β .

The amount of activated protein C generated is directly related to the level of surface TM. The effect of hLTBP-3 over-expression on TM activity on the surface of the cells is a reflection of its effect on TGF β activity.

EXAMPLE 9

EFFECT OF INHIBITING hLTBP-3 WITH ANTISENSE DNA

The oligonucleotides used in antisense experiments are synthesized using phosphorothioates and C-5 propyne pyrimidines. Antisense oligodeoxynucleotides (oligos) are designed to hybridize to the 5' region of the hLTBP-3 mRNA. Cells are plated in 96-well plates at a density of 2000 or 5000 cells/well and allowed to attach overnight in DMEM/F-12 5% FBS. After washing monolayers with serum free medium (SFM), 1 nmol of each oligo is introduced in 100 μ l of SFM. Control wells containing SFM with vehicle alone are included in addition to the sense strand oligo controls. After an overnight incubation in the presence of oligos, test wells are rinsed with SFM and re-charged with oligo overnight as above. On the fourth day each experimental condition is treated with or without TGF β at a concentration of 1 ng/ml (a concentration found to be optimal for PAI-1 and TM response). PAI-1 levels

are assayed 16 hours later from the culture supernatant using a commercially available PAI-1 ELISA kit (American Diagnostica Inc., Greenwich, CT). Cell surface TM levels are assayed in SVHA-1 cells indirectly by measuring the ability of the cell surface TM to activate human protein C.

After the conditioned medium is removed for the PAI-1 assay it is replaced with 100 μ l of SFM containing 25 μ g/ml human protein C and 0.5 units/ml thrombin. After 1 hour incubation at room temperature, 75 μ l aliquots are removed to 96-well plates, each test well containing 50 μ l of 10 U/ml hirudin in activation buffer (20 mM tris pH 7.4, 150 mM NaCl), and incubated 5-10 minutes with agitation. Activated human protein C is then assayed (as a measure of TM activity) by adding 50 μ l of the chromogenic substrate S2366 and measuring the change in absorbance at 405 nm on a 5 minute kinetic run.

Antisense oligos to hLTBP-3 can block the TGF β -dependent suppression of TM surface levels, as measured by the ability of the cells to support the thrombin-dependent activation of human protein C.

EXAMPLE 10

EFFECT OF hLTBP-3 ON TGF β PRODUCTION

A. TGF β /CAT Transfection

In order to determine hLTBP-3 effects on TGF β promoter activity, a TGF β 3 promoter construct driving CAT expression (1 μ g) was co-transfected into ECV304 cells with a hLTBP-3 polypeptide encoding pcineo vector (5 μ g), a TGF β polypeptide encoding pcineo vector (5 μ g), or both. Controls cells are co-transfected with 1 μ g TGF β 3 promoter construct and 10 μ g pcineo vector not either TGF β or hLTBP-3 (Promega, Madison, WI).

Transfection is initiated by plating ECV304 cells at 3×10^5 cells per well in a 6-well plate with DMEM/F12 media in 5% fetal bovine serum (FBS). The cells are allowed to attach overnight at 37°C.

5 Twenty μ l lipofectin are diluted with serum-free medium to a total volume of 200 μ l per transfection and placed at room temperature for 30 to 60 minutes. Eleven μ g DNA is diluted with 200 μ l of serum-free medium and mixed with the lipofectin solution. The resulting reagent mixture is
10 incubated at room temperature for 15 minutes.

The medium is aspirated from the culture plates, and the cultures are washed twice with PBS. Two ml of medium are added per well, and the cells are incubated at 37°C 30 minutes prior to adding the lipofectin reagent dropwise to the cultures.
15 The cultures are then incubated 4-6 hours at 37°C, the medium is aspirated, and fresh DMEM/F12 5% FBS is added.

After culturing for 24 hours, the cells are washed twice with phosphate buffered saline (PBS), and serum free DMEM medium containing 100 μ g/ml Cohn's fractionated bovine serum
20 albumin (BSA) and 2 ng/ml TGF β 3 (R&D Systems) is added. The cells are incubated overnight at 37°C and supernatants are collected and stored frozen. The cells are washed twice with PBS, lysed, and expressed CAT activity is measured kinetically as in Example 1. Lysates are normalized in BCA assay
25 measuring total protein concentration.

B. Endogenous TGF β

Endogenous levels of TGF β 1 and TGF β 3 secreted into the supernatant of the above cultures can also be evaluated by
30 ELISA. Briefly, 96-well plates are coated with 0.5 μ g/ml TGF β RII receptor (R&D systems) at 100 μ l per well in PBS. Plate sealer is added and the plates are stored at 4°C overnight.

The plates are then washed three times with 0.1% Tween 20 in PBS, blocked with 300 μ l PBS containing 5% Tween 20 and 5% sucrose for 1-3 hours at room temp.

Latent TGF β 3 is activated by adding 0.1 ml 1N HCL to 0.5
5 ml supernatant, and incubating 10 minutes at room temperature. The mixture is neutralized with 0.1 ml 1.2 N NaOH and 0.5 M Hepes. The blocking mixture is removed from the prepared plates, and samples are added at 200 μ l per well. Standard TGF β 3, serially diluted from 2 ng/ml to 0.016 ng/ml in PBS 3%
10 BSA, is added at 200 μ l per well.

The plates are incubated for two hours and washed as before. Rabbit anti-TGF β 3 (Santa Cruz catalog# SC-082) is prepared at 1 μ g/ml in PBS 3% BSA, added to the plates at 100
15 μ l per well, incubated for one hour at room temp., and washed as before. Goat anti-Rabbit IgG alkaline phosphate conjugate at 1/250 dilution in PBS 3% goat serum is added to the plates at 100 μ l per well, incubated one hour, and washed as before. One PnPP tablet (Sigma) is prepared in 3 ml H₂O, added at 100
20 μ l per well. The plates are incubated for 20-30 minutes and read at OD 405 nm.

Latent TGF β 1 is activated as described for TGF β 3 and assayed according to directions in a commercial TGF β 1 ELISA kit (R&D Systems).

hLTBP-3 expression is expected to inhibit TGF promoters
25 and the secretion of TGF β .

WO 00/12551

PCT/US99/19436

SEQUENCE LISTING

<110> Edmonds, Brian T.

<120> HUMAN LATENT TRANSFORMING GROWTH FACTOR-BETA BINDING
PROTEIN 3

<130> P-12239

<140>

<141>

<160> 6

<170> PatentIn Ver. 2.0

<210> 1

<211> 3624

<212> DNA

<213> Homo sapiens

<400> 1

```
cggggcgag gggggggcgg ggcgctggcc cgcgagcgct tcaaggtggt ctttgcgccg 60
gtgatctgca agcggacctg tctcaagggc cagtgtcggg acagttgtca gcagggctcc 120
aacatgacgc tcatcggaga gaacggccac agcacagaca cgctcacggg ctccggcttc 180
cgcgtggtgg tgtgccctct cccctgcatg aatggcggcc agtgctcctc gcgaaaccag 240
tgctgtgtc ccccggaact cactgggcgc ttctgccagg tgcccgcagg aggagccggt 300
gggggtaccg gcggtcagg ccccggcctg agcaggacag gggccctgtc cacagggggcg 360
ctgccgcccc tggctccgga gggcgactct gtggccagca agcacgccat ctacgccgtc 420
caggtgatcg ctgacctcc tgggcccggg gaggggcctc ctgccagca cgcagccttc 480
ctggtgcccc taggcccggg acagatctca gcagaagtgc agggcccgc ccccggtggtg 540
aatgtgcgcg tccatcaccg gcccgaggcc tcagtccagg tgcaccgcat tgagagctcg 600
aacgccgaga ggcgagcccc ctcccagcac ctgctgccgc accccaagcc ctgcaccccc 660
cggccgcccc cccagaagtc cctgggcccgc tgctttcagg aactctgcc caagcagccg 720
tgtggcagca accccctccc cggcctcacc aagcaggaag actgctgcgg tagcatcggc 780
actgcctggg gccagagcaa gtgccacaag tgtccccagc tgcagtacac aggagtgcag 840
aagccagggc ctgtacgtgg ggaagtgggc gctgactgtc cccagggcta caagaggctt 900
aacagcaccg actgccagga catcaacgag tgcgcaatgc cgggcgtgtg tcgccatggt 960
gactgcctca acaaccctgg ctccatctgc tgtgtctgcc cacctggcca tagtttaggc 1020
ccctcccgtg cacagtgcac tgcagacaaa ccggaggaga agagcctgtg tttccgcctg 1080
gtgagccctg agcaccagtg ccagcaccga ctgaccaccc gcctgacccg ccagctctgc 1140
tgctgcagtg tcggcaaggc ctggggcgcg cgggtgtcagc gctgcccac agatggcacc 1200
gctgcgttca aggagatctg cccagctggg aagggatacc acattctcac ctcccaccag 1260
acgctcacca ttcaggggcg gagtgacttt tcccttttcc tgcacctga cgggccaccc 1320
aagccccagc agcttccgga gagccctagc caggctccac cacctgagga cacagaggaa 1380
gagagagggg tgaccacgga ctccaccgtg agtgaggaga ggtcagtgc gcagagccac 1440
ccaactgcca ccacgactcc tgcccggccc taccgccagc tgatctcccg tccctcgccc 1500
ccgaccatgc gctggttcct gccggacttg cctccttccc gcagcgccgt agagatcgct 1560
```

WO 00/12551

PCT/US99/19436

```

ccccactcagg tcacagagac tgatgagtgc cgactgaacc agaacatctg tggccacgga 1620
gagtgcgtgc cgggcccccc tgactactcc tgccactgca accccggcta ccggtcacat 1680
ccccagcacc gctactgcgt ggatgtgaac gagtgcgagg cagagccctg tggccccggg 1740
aggggcatct gcatgaacac cggcggctcc tacaattgcc actgcaaccg cggctaccgc 1800
ctgcacgtgg gcgccggggg gcgctcgtgc gtggacctga acgaatgcgc caagccccac 1860
ctgtgcggcg acggcggctt ctgcatcaac tttcccggtc actacaagtg caactgctac 1920
cccggctacc ggctcaaagc ctcccggcct cctgtgtgcg aagacatcga cgagtgccgg 1980
gacccaagct cttgcccgga tggcaaatgc gagaacaagc cggggagctt caagtgcac 2040
gcctgtcagc ctggctaccg cagccagggg ggcggggcct gtcgcgacgt gaacgagtgc 2100
gccgagggca gccctgtctc gcctggctgg tgcgagaacc tcccgggctc cttccgctgc 2160
acctgtgccc agggctacgc gcccgcgccc gacggccgca gttgcttgga tgtggacgag 2220
tgtgaggctg gggacgtgtg tgacaatggc atctgcagca acacgccagg atctttccag 2280
tgtcagtgcc tctctggcta ccatctgtcc agggaccgga gccactgcga ggacattgat 2340
gagtgtgact tccttcgagc ctgcattggg ggtgactgca tcaataccaa tggctcctac 2400
agatgtcttt gccccaggg gcctcggtgc gtgggtggca ggaaatgcca agacatagat 2460
gagtgcagcc aggaccgag cctgtgcctt ccccatgggg cctgcaagaa ccttcagggc 2520
tcctatgtgt gtgtctgcga tgagggttc actcccaccc aggaccagca cggttgtgag 2580
gaggtggagc agccccacca caagaaggag tgctacctga acttcgatga cacagtgttc 2640
tgcgacagcg tattggccac caacgtgacc cagcaggagt gctgctgctc tctgggggcc 2700
ggctggggcg accactgcga aatctacccc tgcccagctc acagctcagc cgagttccac 2760
agcctctgcc cagacggaaa gggctacacc caggacaaca acatcgtcaa ctacggcatc 2820
ccagcccacc gtgacatcga cgagtgcacg ttgttcgggt cggagatttg caaggagggc 2880
aagtgcgtga acacgcagcc tggctacgag tgctactgca agcagggtt ctactacgac 2940
gggaacctgc tggaatgcgt ggacgtggac gagtgcctgg acgagtccaa ctgccggaac 3000
ggagtgtgtg agaacacgcg cggcggctac cgctgtgcct gcacgcccc tgcgagtac 3060
agtcccgcgc agcgccagtg cctgagcccc gaagagatgg agcgtgcccc ggagcggcgc 3120
gacgtgtgct ggagccagcg cggagaggac ggcattgtgc ctggccccct ggccgggcct 3180
gccctcacct tcgacgactg ctgctgccgc cagggccgcg gctggggcgc ccaatgccga 3240
ccgtgccgcg cgcgcggcgc ggggtcccat tgcccacat cgcagagcga gagcaattcc 3300
ttctgggaca caagccccct gctgttgggg aagcccccaa gagatgagga cagttcagag 3360
gaggattcag acgagtgtcg ctgcgtgagt ggcgctgcg tgccgcggcc gggcggcgcc 3420
gtgtgcgagt gtcccggcgg cttccagctc gacgcctccc gcgcccgtg cgtggatatc 3480
gacgagtgcc gagagctgaa ccagcgcggg ctgctgtgca agagcgagcg ctgcgtgaac 3540
accagcggct ccttccgctg cgtctgcaaa gccggcttcg cgcgcagccg cccgcacggg 3600
gcctgcgttc cccagcgccg ccgc

```

<210> 2

<211> 1208

<212> PRT

<213> Homo sapiens

<400> 2

```

Arg Gly Ala Gly Gly Gly Gly Ala Leu Ala Arg Glu Arg Phe Lys Val
  1                      5                      10                      15

```

```

Val Phe Ala Pro Val Ile Cys Lys Arg Thr Cys Leu Lys Gly Gln Cys
          20                      25                      30

```

WO 00/12551

PCT/US99/19436

Arg Asp Ser Cys Gln Gln Gly Ser Asn Met Thr Leu Ile Gly Glu Asn
 35 40 45

Gly His Ser Thr Asp Thr Leu Thr Gly Ser Gly Phe Arg Val Val Val
 50 55 60

Cys Pro Leu Pro Cys Met Asn Gly Gly Gln Cys Ser Ser Arg Asn Gln
 65 70 75 80

Cys Leu Cys Pro Pro Asp Phe Thr Gly Arg Phe Cys Gln Val Pro Ala
 85 90 95

Gly Gly Ala Gly Gly Gly Thr Gly Gly Ser Gly Pro Gly Leu Ser Arg
 100 105 110

Thr Gly Ala Leu Ser Thr Gly Ala Leu Pro Pro Leu Ala Pro Glu Gly
 115 120 125

Asp Ser Val Ala Ser Lys His Ala Ile Tyr Ala Val Gln Val Ile Ala
 130 135 140

Asp Pro Pro Gly Pro Gly Glu Gly Pro Pro Ala Gln His Ala Ala Phe
 145 150 155 160

Leu Val Pro Leu Gly Pro Gly Gln Ile Ser Ala Glu Val Gln Ala Pro
 165 170 175

Pro Pro Val Val Asn Val Arg Val His His Pro Pro Glu Ala Ser Val
 180 185 190

Gln Val His Arg Ile Glu Ser Ser Asn Ala Glu Ser Ala Ala Pro Ser
 195 200 205

Gln His Leu Leu Pro His Pro Lys Pro Ser His Pro Arg Pro Pro Thr
 210 215 220

Gln Lys Ser Leu Gly Arg Cys Phe Gln Asp Thr Leu Pro Lys Gln Pro
 225 230 235 240

Cys Gly Ser Asn Pro Leu Pro Gly Leu Thr Lys Gln Glu Asp Cys Cys
 245 250 255

Gly Ser Ile Gly Thr Ala Trp Gly Gln Ser Lys Cys His Lys Cys Pro
 260 265 270

Gln Leu Gln Tyr Thr Gly Val Gln Lys Pro Gly Pro Val Arg Gly Glu
 275 280 285

WO 00/12551

PCT/US99/19436

Val	Gly	Ala	Asp	Cys	Pro	Gln	Gly	Tyr	Lys	Arg	Leu	Asn	Ser	Thr	His	
290						295					300					
Cys	Gln	Asp	Ile	Asn	Glu	Cys	Ala	Met	Pro	Gly	Val	Cys	Arg	His	Gly	
305					310					315					320	
Asp	Cys	Leu	Asn	Asn	Pro	Gly	Ser	Tyr	Arg	Cys	Val	Cys	Pro	Pro	Gly	
				325					330					335		
His	Ser	Leu	Gly	Pro	Ser	Arg	Thr	Gln	Cys	Ile	Ala	Asp	Lys	Pro	Glu	
			340					345					350			
Glu	Lys	Ser	Leu	Cys	Phe	Arg	Leu	Val	Ser	Pro	Glu	His	Gln	Cys	Gln	
		355					360					365				
His	Pro	Leu	Thr	Thr	Arg	Leu	Thr	Arg	Gln	Leu	Cys	Cys	Cys	Ser	Val	
		370				375					380					
Gly	Lys	Ala	Trp	Gly	Ala	Arg	Cys	Gln	Arg	Cys	Pro	Thr	Asp	Gly	Thr	
385					390					395					400	
Ala	Ala	Phe	Lys	Glu	Ile	Cys	Pro	Ala	Gly	Lys	Gly	Tyr	His	Ile	Leu	
				405					410					415		
Thr	Ser	His	Gln	Thr	Leu	Thr	Ile	Gln	Gly	Glu	Ser	Asp	Phe	Ser	Leu	
			420					425					430			
Phe	Leu	His	Pro	Asp	Gly	Pro	Pro	Lys	Pro	Gln	Gln	Leu	Pro	Glu	Ser	
		435				440						445				
Pro	Ser	Gln	Ala	Pro	Pro	Pro	Glu	Asp	Thr	Glu	Glu	Glu	Arg	Gly	Val	
		450				455					460					
Thr	Thr	Asp	Ser	Pro	Val	Ser	Glu	Glu	Arg	Ser	Val	Gln	Gln	Ser	His	
465					470				475					480		
Pro	Thr	Ala	Thr	Thr	Thr	Pro	Ala	Arg	Pro	Tyr	Pro	Glu	Leu	Ile	Ser	
				485				490					495			
Arg	Pro	Ser	Pro	Pro	Thr	Met	Arg	Trp	Phe	Leu	Pro	Asp	Leu	Pro	Pro	
			500					505				510				
Ser	Arg	Ser	Ala	Val	Glu	Ile	Ala	Pro	Thr	Gln	Val	Thr	Glu	Thr	Asp	
		515				520					525					
Glu	Cys	Arg	Leu	Asn	Gln	Asn	Ile	Cys	Gly	His	Gly	Glu	Cys	Val	Pro	
530					535						540					

WO 00/12551

PCT/US99/19436

Gly	Pro	Pro	Asp	Tyr	Ser	Cys	His	Cys	Asn	Pro	Gly	Tyr	Arg	Ser	His	545	550	555	560
Pro	Gln	His	Arg	Tyr	Cys	Val	Asp	Val	Asn	Glu	Cys	Glu	Ala	Glu	Pro	565	570	575	
Cys	Gly	Pro	Gly	Arg	Gly	Ile	Cys	Met	Asn	Thr	Gly	Gly	Ser	Tyr	Asn	580	585	590	
Cys	His	Cys	Asn	Arg	Gly	Tyr	Arg	Leu	His	Val	Gly	Ala	Gly	Gly	Arg	595	600	605	
Ser	Cys	Val	Asp	Leu	Asn	Glu	Cys	Ala	Lys	Pro	His	Leu	Cys	Gly	Asp	610	615	620	
Gly	Gly	Phe	Cys	Ile	Asn	Phe	Pro	Gly	His	Tyr	Lys	Cys	Asn	Cys	Tyr	625	630	635	640
Pro	Gly	Tyr	Arg	Leu	Lys	Ala	Ser	Arg	Pro	Pro	Val	Cys	Glu	Asp	Ile	645	650	655	
Asp	Glu	Cys	Arg	Asp	Pro	Ser	Ser	Cys	Pro	Asp	Gly	Lys	Cys	Glu	Asn	660	665	670	
Lys	Pro	Gly	Ser	Phe	Lys	Cys	Ile	Ala	Cys	Gln	Pro	Gly	Tyr	Arg	Ser	675	680	685	
Gln	Gly	Gly	Gly	Ala	Cys	Arg	Asp	Val	Asn	Glu	Cys	Ala	Glu	Gly	Ser	690	695	700	
Pro	Cys	Ser	Pro	Gly	Trp	Cys	Glu	Asn	Leu	Pro	Gly	Ser	Phe	Arg	Cys	705	710	715	720
Thr	Cys	Ala	Gln	Gly	Tyr	Ala	Pro	Ala	Pro	Asp	Gly	Arg	Ser	Cys	Leu	725	730	735	
Asp	Val	Asp	Glu	Cys	Glu	Ala	Gly	Asp	Val	Cys	Asp	Asn	Gly	Ile	Cys	740	745	750	
Ser	Asn	Thr	Pro	Gly	Ser	Phe	Gln	Cys	Gln	Cys	Leu	Ser	Gly	Tyr	His	755	760	765	
Leu	Ser	Arg	Asp	Arg	Ser	His	Cys	Glu	Asp	Ile	Asp	Glu	Cys	Asp	Phe	770	775	780	
Pro	Ala	Ala	Cys	Ile	Gly	Gly	Asp	Cys	Ile	Asn	Thr	Asn	Gly	Ser	Tyr	785	790	795	800

WO 00/12551

PCT/US99/19436

Arg Cys Leu Cys Pro Gln Gly His Arg Leu Val Gly Gly Arg Lys Cys
 805 810 815

Gln Asp Ile Asp Glu Cys Ser Gln Asp Pro Ser Leu Cys Leu Pro His
 820 825 830

Gly Ala Cys Lys Asn Leu Gln Gly Ser Tyr Val Cys Val Cys Asp Glu
 835 840 845

Gly Phe Thr Pro Thr Gln Asp Gln His Gly Cys Glu Glu Val Glu Gln
 850 855 860

Pro His His Lys Lys Glu Cys Tyr Leu Asn Phe Asp Asp Thr Val Phe
 865 870 875 880

Cys Asp Ser Val Leu Ala Thr Asn Val Thr Gln Gln Glu Cys Cys Cys
 885 890 895

Ser Leu Gly Ala Gly Trp Gly Asp His Cys Glu Ile Tyr Pro Cys Pro
 900 905 910

Val Tyr Ser Ser Ala Glu Phe His Ser Leu Cys Pro Asp Gly Lys Gly
 915 920 925

Tyr Thr Gln Asp Asn Asn Ile Val Asn Tyr Gly Ile Pro Ala His Arg
 930 935 940

Asp Ile Asp Glu Cys Met Leu Phe Gly Ser Glu Ile Cys Lys Glu Gly
 945 950 955 960

Lys Cys Val Asn Thr Gln Pro Gly Tyr Glu Cys Tyr Cys Lys Gln Gly
 965 970 975

Phe Tyr Tyr Asp Gly Asn Leu Leu Glu Cys Val Asp Val Asp Glu Cys
 980 985 990

Leu Asp Glu Ser Asn Cys Arg Asn Gly Val Cys Glu Asn Thr Arg Gly
 995 1000 1005

Gly Tyr Arg Cys Ala Cys Thr Pro Pro Ala Glu Tyr Ser Pro Ala Gln
 1010 1015 1020

Arg Gln Cys Leu Ser Pro Glu Glu Met Glu Arg Ala Pro Glu Arg Arg
 1025 1030 1035 1040

Asp Val Cys Trp Ser Gln Arg Gly Glu Asp Gly Met Cys Ala Gly Pro
 1045 1050 1055

WO 00/12551

PCT/US99/19436

Leu Ala Gly Pro Ala Leu Thr Phe Asp Asp Cys Cys Cys Arg Gln Gly
 1060 1065 1070

Arg Gly Trp Gly Ala Gln Cys Arg Pro Cys Pro Pro Arg Gly Ala Gly
 1075 1080 1085

Ser His Cys Pro Thr Ser Gln Ser Glu Ser Asn Ser Phe Trp Asp Thr
 1090 1095 1100

Ser Pro Leu Leu Leu Gly Lys Pro Pro Arg Asp Glu Asp Ser Ser Glu
 1105 1110 1115 1120

Glu Asp Ser Asp Glu Cys Arg Cys Val Ser Gly Arg Cys Val Pro Arg
 1125 1130 1135

Pro Gly Gly Ala Val Cys Glu Cys Pro Gly Gly Phe Gln Leu Asp Ala
 1140 1145 1150

Ser Arg Ala Arg Cys Val Asp Ile Asp Glu Cys Arg Glu Leu Asn Gln
 1155 1160 1165

Arg Gly Leu Leu Cys Lys Ser Glu Arg Cys Val Asn Thr Ser Gly Ser
 1170 1175 1180

Phe Arg Cys Val Cys Lys Ala Gly Phe Ala Arg Ser Arg Pro His Gly
 1185 1190 1195 1200

Ala Cys Val Pro Gln Arg Arg Arg
 1205

<210> 3

<211> 3771

<212> DNA

<213> Homo sapiens

<400> 3

cgggggcgag gcggggggcgg ggcgctggcc cgcgagcgct tcaaggtggt ctttgcgccg 60
 gtgatctgca agcggacctg tctcaagggc cagtgtcggg acagttgtca gcagggtctc 120
 aacatgacgc tcatcggaga gaacggccac agcacagaca cgctcacggg ctccggcttc 180
 cgcgtggtgg tgtgccctct cccctgcatg aatggcggcc agtgctcctc gcgaaaccag 240
 tgccctgtgc ccccggactt cactgggcgc ttctgccagg tgcccgcagg aggagccggt 300
 ggggggtaccg gcggctcagg ccccggcctg agcaggacag gggccctgtc cacagggggcg 360
 ctgccgcccc tggctccgga gggcgactct gtggccagca agcacgccat ctacgcogtc 420
 caggtgatcg ctgacctctc tgggcccggg gaggggcctc ctgcccagca cgcagccttc 480
 ctggtgcccc taggcccggg acagatctca gcagaaggta ccaggcaact ggcaaaccgc 540
 ggaaggtcgc cagtgggtgg gcactagggg ggccagggca gggcagggtc agccctggag 600
 gagctcagcg cggtgacctg cggcgcggtg cgggcagccc tgaggccacc gcgcccgcgc 660

WO 00/12551

PCT/US99/19436

```

ccagtgcagg ccccgccccc cgtggtgaat gtgcgcgtcc atcaccgcgc cgaggcctca 720
gtccaggtgc accgcattga gagctcgaac gccgagagcg cagccccctc ccagcacctg 780
ctgccgcacc ccaagccctc gcaccccccg ccgcccaccc agaagtccct gggccgctgc 840
tttcaggaca ctctgccc aa gcagccgtgt ggcagcaacc ccctcccccg cctcaccaag 900
caggaagact gctgcggtag catcggcact gcctgggggc agagcaagtg ccacaagtgt 960
ccccagctgc agtacacagg agtgcagaag ccagggcctg tacgtgggga agtgggctgt 1020
gactgtcccc agggctacaa gaggcttaac agcaccact gccaggacat caacgagtgc 1080
gcaatgccgg gcgtgtgtcg ccatggtgac tgccctcaaca accctggctc ctatcgctgt 1140
gtctgcccac ctggccatag tttaggcccc tcccgtaac agtgcattgc agacaaaccg 1200
gaggagaaga gcctgtgttt ccgcctggtg agccctgagc accagtcca gcacccactg 1260
accaccgcgc tgaccgcga gctctgctgc tgcagtgtcg gcaaggcctg gggcgcgcg 1320
tgtcagcgct gcccaacaga tggcaccgct gcgttcaagg agatctgcc agctgggaag 1380
ggataccaca ttctcacctc ccaccagacg ctccaccattc agggcgagag tgacttttcc 1440
cttttcctgc accctgacgg gccacccaag cccagcagc ttcgggagag ccctagccag 1500
gctccaccac ctgaggacac agaggaagag agaggggtga ccacggactc accggtgagt 1560
gaggagaggt cagtgcagca gagccacca actgccacca cgactcctgc ccggccctac 1620
cccgagctga tctcccgctc ctgcaccccg accatgcgct ggttcctgcc ggacttgct 1680
ccttcccgca gcgcgtaga gatcgctccc actcaggctc cagagactga tgagtgccga 1740
ctgaaccaga acatctgtgg ccacggagag tgcgtgccgg gccccctga ctactcctgc 1800
cactgcaacc ccggctaccg gtcacatccc cagcaccgct actgcgtgga tgtgaacgag 1860
tgcgaggcag agccctgtgg ccgggggagg ggcattctga tgaacaccgg cggctcctac 1920
aattgccact gcaaccgcgg ctaccgcctg cacgtgggcg ccggggggcg ctcgctgcgtg 1980
gacctgaacg aatgcgcaa gcccacctg tgcggcgacg gcggcttctg catcaacttt 2040
cccggtcact acaagtgcaa ctgctacccc ggctaccggc tcaaagcctc ccggcctcct 2100
gtgtgcgaag acatcgacga gtgccgggac ccaagctctt gccgggatgg caaatgcgag 2160
aacaagcccg ggagcttcaa gtgcatcgcc tgtcagcctg gctaccgcag ccaggggggc 2220
ggggcctgtc gcgacgtgaa cgagtgcgcc gagggcagcc cctgctcgcc tggctggtgc 2280
gagaacctcc cgggctcctt ccgctgcacc tgtgcccagg gctacgcgcc cgcgcccagc 2340
ggccgcagtt gcttggtgtt ggacgagtgt gaggtggtgg acgtgtgtga caatggcatc 2400
tgcagcaaca cgcagagatc tttccagtgt cagtgcctct ctggtacca tctgtccagg 2460
gaccggagcc actgcgagga cattgatgag tgtgacttcc ctgcagcctg cattgggggt 2520
gactgcatca ataccaatgg ctctacaga tgtctttgcc cccaggggca tcggctggtg 2580
ggtggcagga aatgccaaga catagatgag tgcagccagg acccgagcct gtgccttccc 2640
catggggcct gcaagaacct tcagggtccc tatgtgtgtg tctgcgatga gggcttccact 2700
cccaccagg accagcacgg ttgtgaggag gtggagcagc cccaccacaa gaaggagtgc 2760
tacctgaact tcgatgacac agtgttctgc gacagcgtat tggccaccaa cgtgaccag 2820
caggagtgtc gctgctctct gggggccggc tggggcgacc actgcgaaat ctaccctgc 2880
ccagtctaca gctcagccga gttccacagc ctctgcccag acggaaaggg ctacaccag 2940
gacaacaaca tcgtcaacta cggcatccca gccaccgtg acatcgacga gtgcatgttg 3000
ttcgggtcgg agatttgcaa ggagggcaag tgcgtgaaca cgcagcctgg ctacgagtgc 3060
tactgcaagc agggcttcta ctacgacggg aacctgctgg aatgcgtgga cgtggacgag 3120
tgccctggac agtccaactg ccggaacgga gtgtgtgaga acacgcgcgg cggctaccgc 3180
tgtgcctgca cgcctcctgc cgagtacagt ccgcgcagc gccagtgcct gagcccggaa 3240
gagatggagc gtgccccgga gcggcgcgac gtgtgctgga gccagcgcg agaggacggc 3300
atgtgcgctg gccccctggc cgggcctgcc ctcccttcg acgactgctg ctgccgccag 3360
ggccgcggct ggggcgccc atgccgacc tggccgcgc gcggcgcggg gtccattgc 3420
ccgacatcgc agagcgagag caattccttc tgggacacaa gccccctgct gttggggaag 3480
ccccaagag atgaggacag ttcagaggag gattcagacg agtgtcgctg cgtgagtggc 3540

```

WO 00/12551

PCT/US99/19436

cgctgcgtgc cgcggccggg cggcgccgtg tgcgagtgtc ccggcggcctt ccagctcgac 3600
gcctcccgcg cccgctgcgt ggatatcgac gagtgccgag agctgaacca gcgcgggctg 3660
ctgtgcaaga gcgagcgctg cgtgaacacc agcggctcct tccgctgcgt ctgcaaagcc 3720
ggcttcgcgc gcagccgccc gcacggggcc tgcgttcccc agcgcgcgcg c 3771

<210> 4

<211> 188

<212> PRT

<213> Homo sapiens

<400> 4

Arg Gly Ala Gly Gly Gly Gly Ala Leu Ala Arg Glu Arg Phe Lys Val
1 5 10 15

Val Phe Ala Pro Val Ile Cys Lys Arg Thr Cys Leu Lys Gly Gln Cys
20 25 30

Arg Asp Ser Cys Gln Gln Gly Ser Asn Met Thr Leu Ile Gly Glu Asn
35 40 45

Gly His Ser Thr Asp Thr Leu Thr Gly Ser Gly Phe Arg Val Val Val
50 55 60

Cys Pro Leu Pro Cys Met Asn Gly Gly Gln Cys Ser Ser Arg Asn Gln
65 70 75 80

Cys Leu Cys Pro Pro Asp Phe Thr Gly Arg Phe Cys Gln Val Pro Ala
85 90 95

Gly Gly Ala Gly Gly Gly Thr Gly Gly Ser Gly Pro Gly Leu Ser Arg
100 105 110

Thr Gly Ala Leu Ser Thr Gly Ala Leu Pro Pro Leu Ala Pro Glu Gly
115 120 125

Asp Ser Val Ala Ser Lys His Ala Ile Tyr Ala Val Gln Val Ile Ala
130 135 140

Asp Pro Pro Gly Pro Gly Glu Gly Pro Pro Ala Gln His Ala Ala Phe
145 150 155 160

Leu Val Pro Leu Gly Pro Gly Gln Ile Ser Ala Glu Gly Thr Arg Gln
165 170 175

Leu Ala Asn Pro Gly Arg Ser Pro Val Gly Gly His
180 185

WO 00/12551

PCT/US99/19436

<210> 5
 <211> 41
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:Signal peptide
 sequence

<400> 5
 Met Arg Gln Ala Gly Gly Leu Gly Leu Leu Ala Leu Leu Leu Leu Ala
 1 5 10 15
 Leu Leu Gly Pro Gly Gly Arg Gly Val Gly Arg Pro Gly Ser Gly Ala
 20 25 30
 Gln Ala Gly Ala Gly Arg Trp Ala Gln
 35 40

<210> 6
 <211> 1257
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Xaa = any amino acid encoding codon or nonsense
 codon

<400> 6
 Arg Gly Ala Gly Gly Gly Gly Ala Leu Ala Arg Glu Arg Phe Lys Val
 1 5 10 15
 Val Phe Ala Pro Val Ile Cys Lys Arg Thr Cys Leu Lys Gly Gln Cys
 20 25 30
 Arg Asp Ser Cys Gln Gln Gly Ser Asn Met Thr Leu Ile Gly Glu Asn
 35 40 45
 Gly His Ser Thr Asp Thr Leu Thr Gly Ser Gly Phe Arg Val Val Val
 50 55 60
 Cys Pro Leu Pro Cys Met Asn Gly Gly Gln Cys Ser Ser Arg Asn Gln
 65 70 75 80
 Cys Leu Cys Pro Pro Asp Phe Thr Gly Arg Phe Cys Gln Val Pro Ala
 85 90 95

WO 00/12551

PCT/US99/19436

Gly Gly Ala Gly Gly Gly Thr Gly Gly Ser Gly Pro Gly Leu Ser Arg
 100 105 110

Thr Gly Ala Leu Ser Thr Gly Ala Leu Pro Pro Leu Ala Pro Glu Gly
 115 120 125

Asp Ser Val Ala Ser Lys His Ala Ile Tyr Ala Val Gln Val Ile Ala
 130 135 140

Asp Pro Pro Gly Pro Gly Glu Gly Pro Pro Ala Gln His Ala Ala Phe
 145 150 155 160

Leu Val Pro Leu Gly Pro Gly Gln Ile Ser Ala Glu Gly Thr Arg Gln
 165 170 175

Leu Ala Asn Pro Gly Arg Ser Pro Val Gly Gly His Xaa Gly Gly Gln
 180 185 190

Gly Arg Ala Gly Ser Ala Leu Glu Glu Leu Ser Ala Val Thr Arg Gly
 195 200 205

Ala Val Arg Ala Ala Leu Arg Pro Pro Arg Pro Pro Pro Val Gln Ala
 210 215 220

Pro Pro Pro Val Val Asn Val Arg Val His His Pro Pro Glu Ala Ser
 225 230 235 240

Val Gln Val His Arg Ile Glu Ser Ser Asn Ala Glu Ser Ala Ala Pro
 245 250 255

Ser Gln His Leu Leu Pro His Pro Lys Pro Ser His Pro Arg Pro Pro
 260 265 270

Thr Gln Lys Ser Leu Gly Arg Cys Phe Gln Asp Thr Leu Pro Lys Gln
 275 280 285

Pro Cys Gly Ser Asn Pro Leu Pro Gly Leu Thr Lys Gln Glu Asp Cys
 290 295 300

Cys Gly Ser Ile Gly Thr Ala Trp Gly Gln Ser Lys Cys His Lys Cys
 305 310 315 320

Pro Gln Leu Gln Tyr Thr Gly Val Gln Lys Pro Gly Pro Val Arg Gly
 325 330 335

Glu Val Gly Ala Asp Cys Pro Gln Gly Tyr Lys Arg Leu Asn Ser Thr
 340 345 350

WO 00/12551

PCT/US99/19436

His Cys Gln Asp Ile Asn Glu Cys Ala Met Pro Gly Val Cys Arg His
 355 360 365

Gly Asp Cys Leu Asn Asn Pro Gly Ser Tyr Arg Cys Val Cys Pro Pro
 370 375 380

Gly His Ser Leu Gly Pro Ser Arg Thr Gln Cys Ile Ala Asp Lys Pro
 385 390 395 400

Glu Glu Lys Ser Leu Cys Phe Arg Leu Val Ser Pro Glu His Gln Cys
 405 410 415

Gln His Pro Leu Thr Thr Arg Leu Thr Arg Gln Leu Cys Cys Cys Ser
 420 425 430

Val Gly Lys Ala Trp Gly Ala Arg Cys Gln Arg Cys Pro Thr Asp Gly
 435 440 445

Thr Ala Ala Phe Lys Glu Ile Cys Pro Ala Gly Lys Gly Tyr His Ile
 450 455 460

Leu Thr Ser His Gln Thr Leu Thr Ile Gln Gly Glu Ser Asp Phe Ser
 465 470 475 480

Leu Phe Leu His Pro Asp Gly Pro Pro Lys Pro Gln Gln Leu Pro Glu
 485 490 495

Ser Pro Ser Gln Ala Pro Pro Pro Glu Asp Thr Glu Glu Glu Arg Gly
 500 505 510

Val Thr Thr Asp Ser Pro Val Ser Glu Glu Arg Ser Val Gln Gln Ser
 515 520 525

His Pro Thr Ala Thr Thr Thr Pro Ala Arg Pro Tyr Pro Glu Leu Ile
 530 535 540

Ser Arg Pro Ser Pro Pro Thr Met Arg Trp Phe Leu Pro Asp Leu Pro
 545 550 555 560

Pro Ser Arg Ser Ala Val Glu Ile Ala Pro Thr Gln Val Thr Glu Thr
 565 570 575

Asp Glu Cys Arg Leu Asn Gln Asn Ile Cys Gly His Gly Glu Cys Val
 580 585 590

Pro Gly Pro Pro Asp Tyr Ser Cys His Cys Asn Pro Gly Tyr Arg Ser
 595 600 605

WO 00/12551

PCT/US99/19436

His Pro Gln His Arg Tyr Cys Val Asp Val Asn Glu Cys Glu Ala Glu
 610 615 620

Pro Cys Gly Pro Gly Arg Gly Ile Cys Met Asn Thr Gly Gly Ser Tyr
 625 630 635 640

Asn Cys His Cys Asn Arg Gly Tyr Arg Leu His Val Gly Ala Gly Gly
 645 650 655

Arg Ser Cys Val Asp Leu Asn Glu Cys Ala Lys Pro His Leu Cys Gly
 660 665 670

Asp Gly Gly Phe Cys Ile Asn Phe Pro Gly His Tyr Lys Cys Asn Cys
 675 680 685

Tyr Pro Gly Tyr Arg Leu Lys Ala Ser Arg Pro Pro Val Cys Glu Asp
 690 695 700

Ile Asp Glu Cys Arg Asp Pro Ser Ser Cys Pro Asp Gly Lys Cys Glu
 705 710 715 720

Asn Lys Pro Gly Ser Phe Lys Cys Ile Ala Cys Gln Pro Gly Tyr Arg
 725 730 735

Ser Gln Gly Gly Gly Ala Cys Arg Asp Val Asn Glu Cys Ala Glu Gly
 740 745 750

Ser Pro Cys Ser Pro Gly Trp Cys Glu Asn Leu Pro Gly Ser Phe Arg
 755 760 765

Cys Thr Cys Ala Gln Gly Tyr Ala Pro Ala Pro Asp Gly Arg Ser Cys
 770 775 780

Leu Asp Val Asp Glu Cys Glu Ala Gly Asp Val Cys Asp Asn Gly Ile
 785 790 795 800

Cys Ser Asn Thr Pro Gly Ser Phe Gln Cys Gln Cys Leu Ser Gly Tyr
 805 810 815

His Leu Ser Arg Asp Arg Ser His Cys Glu Asp Ile Asp Glu Cys Asp
 820 825 830

Phe Pro Ala Ala Cys Ile Gly Gly Asp Cys Ile Asn Thr Asn Gly Ser
 835 840 845

Tyr Arg Cys Leu Cys Pro Gln Gly His Arg Leu Val Gly Gly Arg Lys
 850 855 860

WO 00/12551

PCT/US99/19436

Cys Gln Asp Ile Asp Glu Cys Ser Gln Asp Pro Ser Leu Cys Leu Pro
 865 870 875 880

His Gly Ala Cys Lys Asn Leu Gln Gly Ser Tyr Val Cys Val Cys Asp
 885 890 895

Glu Gly Phe Thr Pro Thr Gln Asp Gln His Gly Cys Glu Glu Val Glu
 900 905 910

Gln Pro His His Lys Lys Glu Cys Tyr Leu Asn Phe Asp Asp Thr Val
 915 920 925

Phe Cys Asp Ser Val Leu Ala Thr Asn Val Thr Gln Gln Glu Cys Cys
 930 935 940

Cys Ser Leu Gly Ala Gly Trp Gly Asp His Cys Glu Ile Tyr Pro Cys
 945 950 955 960

Pro Val Tyr Ser Ser Ala Glu Phe His Ser Leu Cys Pro Asp Gly Lys
 965 970 975

Gly Tyr Thr Gln Asp Asn Asn Ile Val Asn Tyr Gly Ile Pro Ala His
 980 985 990

Arg Asp Ile Asp Glu Cys Met Leu Phe Gly Ser Glu Ile Cys Lys Glu
 995 1000 1005

Gly Lys Cys Val Asn Thr Gln Pro Gly Tyr Glu Cys Tyr Cys Lys Gln
 1010 1015 1020

Gly Phe Tyr Tyr Asp Gly Asn Leu Leu Glu Cys Val Asp Val Asp Glu
 1025 1030 1035 1040

Cys Leu Asp Glu Ser Asn Cys Arg Asn Gly Val Cys Glu Asn Thr Arg
 1045 1050 1055

Gly Gly Tyr Arg Cys Ala Cys Thr Pro Pro Ala Glu Tyr Ser Pro Ala
 1060 1065 1070

Gln Arg Gln Cys Leu Ser Pro Glu Glu Met Glu Arg Ala Pro Glu Arg
 1075 1080 1085

Arg Asp Val Cys Trp Ser Gln Arg Gly Glu Asp Gly Met Cys Ala Gly
 1090 1095 1100

Pro Leu Ala Gly Pro Ala Leu Thr Phe Asp Asp Cys Cys Cys Arg Gln
 1105 1110 1115 1120

WO 00/12551

PCT/US99/19436

Gly Arg Gly Trp Gly Ala Gln Cys Arg Pro Cys Pro Pro Arg Gly Ala
 1125 1130 1135

Gly Ser His Cys Pro Thr Ser Gln Ser Glu Ser Asn Ser Phe Trp Asp
 1140 1145 1150

Thr Ser Pro Leu Leu Leu Gly Lys Pro Pro Arg Asp Glu Asp Ser Ser
 1155 1160 1165

Glu Glu Asp Ser Asp Glu Cys Arg Cys Val Ser Gly Arg Cys Val Pro
 1170 1175 1180

Arg Pro Gly Gly Ala Val Cys Glu Cys Pro Gly Gly Phe Gln Leu Asp
 1185 1190 1195 1200

Ala Ser Arg Ala Arg Cys Val Asp Ile Asp Glu Cys Arg Glu Leu Asn
 1205 1210 1215

Gln Arg Gly Leu Leu Cys Lys Ser Glu Arg Cys Val Asn Thr Ser Gly
 1220 1225 1230

Ser Phe Arg Cys Val Cys Lys Ala Gly Phe Ala Arg Ser Arg Pro His
 1235 1240 1245

Gly Ala Cys Val Pro Gln Arg Arg Arg
 1250 1255

WE CLAIM:

1. An isolated hLTBP-3 polypeptide comprising at least 20 contiguous amino acids of a polypeptide selected from the group consisting of:
 - 5 a) SEQ ID NO: 2;
 - b) SEQ ID NO: 4; and
 - c) SEQ ID NO: 6.
- 10 2. An isolated nucleic acid encoding an hLTBP-3 polypeptide of claim 1.
- 15 3. An isolated nucleic acid that encodes at least one hLTBP-3 polypeptide of claim 1 wherein said nucleic acid comprises at least 14 contiguous nucleotides from a polynucleotide selected from the group consisting of:
 - a) SEQ ID NO: 1; and
 - b) SEQ ID NO: 3.
- 20 4. An isolated nucleic acid molecule comprising a polynucleotide that hybridizes under stringent conditions to at least 14 contiguous nucleotides of SEQ ID NO: 1, SEQ ID NO: 3, or a polynucleotide complementary thereto.
- 25 5. An isolated nucleic acid that encodes an hLTBP-3 polypeptide which can antagonize TGF β activity, wherein said nucleic acid hybridizes under stringent conditions to at least 20 contiguous nucleotides of SEQ ID NOS: 1, 3, or a polynucleotide complimentary thereto.
- 30 6. A vector comprising said isolated nucleic acid of any of the claims 2-5.
- 35 7. A vector, as in claim 6, wherein said isolated nucleic acid compound is operably-linked to a promoter sequence.

8. A host cell comprising a vector of claim 6 or claim 7.

9. A host cell comprising a vector of claim 6 or
5 claim 7.

10. A method for constructing at least one recombinant host cell, which comprises introducing into said host cell a nucleic acid according to any of claims 2-5.
10

11. A method for expressing at least one hLTBP-3 polypeptide in a recombinant host cell of claim 10, wherein said method comprises culturing at least one said recombinant host cell under conditions suitable for
15 expression of said hLTBP-3 polypeptide.

12. A method for identifying compounds that bind an isolated hLTBP-3 polypeptide according to claim 1, which comprises:
20 a) admixing said isolated hLTBP-3 polypeptide with at least one test compound; and
b) detecting at least one binding interaction between said hLTBP-3 polypeptide and at least one said compound.
13. An antibody that selectively binds an epitope
25 specific for an hLTBP-3 polypeptide according to claim 1.

14. A composition comprising an hLTBP-3 polypeptide according to claim 1 and at least one carrier, excipient, or diluent thereof.
30

15. A method for inhibiting tissue growth *in vitro* or *in vivo*, which comprises administering to a patient in need thereof a tissue growth inhibiting effective amount of at least one composition according to claim 14.
35

16. A method for inhibiting tumor growth, which comprises administering to a patient in need thereof a tumor cell growth inhibiting effective amount of at least one composition according to claim 14.

5

17. An antibody that binds at least one epitope specific to a polypeptide comprising at least 20 amino acids of a polypeptide selected from the group consisting of:

- a) SEQ ID NO:2;
- 10 b) SEQ ID NO:4;
- c) SEQ ID NO:5; and
- d) SEQ ID NO:6.

18. A method for stimulating tissue growth, which
15 comprises administering to a patient in need thereof a tissue growth stimulating effective amount of at least one composition according to claim 14.

19. A method for inhibiting tissue growth, which
20 comprises administering to a patient in need thereof a tissue growth stimulating effective amount of a compound which binds to an hLTBP-3 polypeptide according to claim 1.

20. A method for inhibiting tumor growth, which
25 comprises administering to a patient in need thereof a tumor growth inhibiting effective amount of a compound which binds to an hLTBP-3 polypeptide according to claim 1.

21. A method for stimulating tissue growth, which
30 comprises administering to a patient in need thereof a tissue stimulating effective amount of a compound which binds to an hLTBP-3 polypeptide according to claim 1.

35

22. A method for modulating at least one TGF β regulatable activity in at least one cell, comprising contacting said at least one cell with at least one compound that modulates expression of, or the activity of the protein
5 product of, a nucleic acid molecule having at least 90% identity to at least 40 contiguous nucleotides of a nucleic acid selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, a nucleic acid molecule that is complementary to SEQ ID NO:1, a nucleic acid molecule that is complementary
10 to SEQ ID NO:3, and at least one fragment thereof.

23. The method of claim 22 wherein the nucleic acid molecule has at least 95% identity to at least 40 contiguous nucleotides of a nucleic acid selected from the group
15 consisting of SEQ ID NO:1, SEQ ID NO:3, a nucleic acid molecule that is complementary to SEQ ID NO:1, a nucleic acid molecule that is complementary to SEQ ID NO:3, and at least one fragment thereof.

20 24. The method of claims 22 and 23 wherein said TGF β regulatable activity is at least one selected from the group consisting of:

- (a) plasminogen activator inhibitor-1 expression;
- (b) plasminogen activator inhibitor 1 activity;
- 25 (c) plasminogen activator inhibitor-1 secretion;
- (d) thrombomodulin expression;
- (e) thrombomodulin activity;
- (f) TGF β secretion; and
- (g) cellular proliferation.

25. A method for modulating a TGF β regulatable activity, comprising administering to a cell, cells, or a patient in need of such treatment, a protein encoded by a nucleic acid molecule having at least 90% identity to at least 40
5 contiguous nucleotides of a nucleic acid selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, and at least one fragment thereof.

26. A method for modulating a TGF β regulatable activity,
10 comprising administering to at least one cell, an organism, or a patient in need of such treatment, an antisense nucleic acid molecule having a nucleotide sequence complementary to at least 10 contiguous nucleotides of an mRNA transcribed from a nucleotide sequence selected from the group consisting of SEQ
15 ID NO:1, SEQ ID NO:3, and at least one fragment thereof, wherein said antisense nucleic acid molecule hybridizes to said contiguous sequence such that translation of said mRNA is inhibited.

20 27. A method for the prevention and/or treatment of a disease arising from cellular effects induced by TGF β , said method comprising administering to a patient in need of such treatment a compound that modulates expression of, or the activity of the protein product of, a nucleic acid molecule
25 comprising at least 40 nucleotides selected from the group consisting of:

- a) SEQ ID NO:1;
- b) SEQ ID NO:3; and
- c) at least one fragment thereof.

30

28. A method according to claim 27 wherein the disease to be prevented or treated is at least one selected from the group consisting of: cancer, fibrosis, osteoporosis, myocardial infarction, congestive heart failure, dilated

cardiomyopathy, deep venous thrombosis, disseminated
intravascular thrombosis, stroke, sepsis, injuries involving
major tissue damage and trauma, systemic inflammatory response
syndrome, sepsis syndrome, septic shock, multiple organ
5 dysfunction syndrome (including DIC), atherosclerotic plaque
rupture, and associated sequela arising therefrom.

29. The use of a compound for the manufacture of a
medicament for the treatment or prevention of a disease in
10 which TGF β is responsible for inducing cellular effects that
lead to said disease wherein said compound modulates
expression of, or the activity of the protein product of, a
nucleic acid molecule having at least 90% homology from a
molecule selected from the group consisting of SEQ ID NO:1,
15 SEQ ID NO:3, and fragments thereof.

30. The use of a compound for the manufacture of a
medicament for the prevention of a disease in which TGF β is
responsible for inducing cellular effects that lead to said
20 disease wherein said compound has at least 90% identity to a
member selected from the group consisting of: SEQ ID NO:2, SEQ
ID NO:4, SEQ ID NO:6, and fragments thereof.

31. The use of a compound as claimed in Claim 29 or 30
25 for the manufacture of a medicament for the prevention and/or
treatment of disease wherein the disease to be prevented is
selected from the group consisting of cancer, fibrosis,
osteoporosis, myocardial infarction, congestive heart failure,
dilated cardiomyopathy, deep venous thrombosis, disseminated
30 intravascular thrombosis, stroke, sepsis, injuries involving
major tissue damage and trauma, systemic inflammatory response
syndrome, sepsis syndrome, septic shock, multiple organ
dysfunction syndrome (including DIC), atherosclerotic plaque
rupture, and associated sequela arising therefrom.